


Reference Data

(Consolidated Financial Results for Q3 FY2013)



Daiichi-Sankyo

January 31, 2014

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

MEMO

(This page is intentionally left blank)

Contents

1.	Consolidated Income Statement	P1
2.	Currency Rate	P1
3.	Segment Information	P2
4.	Sales by Business Units	P3
5.	Sales of Global Products	P6
6.	Number of Employees	P7
7.	Consolidated Balance Sheets	P8
8.	Consolidated Statements of Cash Flow	P10
9.	Summary of Product Outlines	P11
10.	Major R&D Pipeline (Innovative pharmaceuticals)	P12

Supplemental Information

Historical Data

1. Summary of Consolidated Income Statement

JPY Bn	Q1			Q2			Q3			Q4			Q3 YTD					FY2013			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY	to forecast	to sales	Forecast	YoY	YoY
Net sales	100%	252.5	+4.1%	100%	263.9	+9.3%	100%	290.7	+11.2%				100%	807.1	61.4	+8.2%	73%	100%	1,110.0	112.1	+11.2%
Cost of sales	33%	83.7	+25.7%	31%	82.8	+7.3%	34%	100.1	+15.8%				33%	266.6	36.3	+15.8%	71%	34%	376.0	62.3	+19.9%
Gross Profit	67%	168.8	-4.1%	69%	181.1	+10.2%	66%	190.6	+8.9%				67%	540.5	25.1	+4.9%	74%	66%	734.0	49.8	+7.3%
SG&A expenses	59%	148.0	+3.2%	55%	146.2	+4.6%	50%	146.2	+5.5%				55%	440.4	18.6	+4.4%	70%	57%	629.0	45.3	+7.8%
R&D expenses	20%	50.0	+18.9%	17%	44.9	-0.6%	14%	42.1	-5.6%				17%	137.0	5.1	+3.9%	72%	17%	191.0	8.0	+4.3%
A&P expenses	10%	24.7	+8.8%	10%	25.5	+18.4%	9%	26.7	+5.4%				10%	76.9	7.3	+10.5%			not disclosed		
Personnel expenses	15%	38.2	+10.0%	15%	39.4	+15.2%	14%	40.3	+18.3%				15%	117.9	14.9	+14.4%			not disclosed		
Other SG&A expenses	14%	35.1	-20.1%	14%	36.4	-6.3%	13%	37.1	+7.3%				13%	108.7	-8.8	-7.5%			not disclosed		
Operating Income	8%	20.8	-36.2%	13%	34.9	+42.2%	15%	44.4	+21.8%				12%	100.1	6.5	+7.0%	95%	9%	105.0	4.5	+4.5%
Non-operating income / expenses		2.6			-11.2			-3.0						-11.6	-13.8				-15.0	-13.6	
Non-operating income		6.5			0.9			2.0						9.4	-3.7				not disclosed		
Non-operating expenses		3.9			12.2			4.9						21.0	10.1				not disclosed		
Ordinary Income	9%	23.3	-42.9%	9%	23.7	+162.0%	14%	41.4	-9.6%				11%	88.5	-7.2	-7.6%	98%	8%	90.0	-9.1	-9.2%
Extraordinary income / losses		-10.1			5.3			19.1						14.4	24.7				12.0	19.1	
Extraordinary income		1.6			6.0			25.1						32.7	29.5				not disclosed		
Extraordinary losses		11.7			0.7			6.0						18.4	4.9				not disclosed		
Income before income taxes and minority interests	5%	13.2	-68.0%	11%	29.0	+658.8%	21%	60.6	+50.8%				13%	102.8	17.4	+20.4%	101%	9%	102.0	9.9	+10.8%
Income taxes / minority interests		2.2			9.2			16.5						27.9	-6.0				37.0	11.5	
Income taxes		1.9			11.4			19.2						32.5	2.6				not disclosed		
Minority interests		0.3			-2.3			-2.7						-4.6	-8.6				not disclosed		
Net Income	4%	11.0	-46.0%	8%	19.8	+401.5%	15%	44.1	+62.4%				9%	74.9	23.4	+45.4%	115%	6%	65.0	-1.6	-2.4%
Effective tax rate		15%			39%			32%						32%							
Overseas sales ratio results		53%			50%			47%						50%							

Notes to FY2013 Q3 YTD Results Year-on-Year Comparisons

Net Sales	Japan company +27.8 (Nexium +27.5, Mema +6.5, Ranmark +2.8, Vaccines +2.8, Mevalotin -2.8) Daiichi Sankyo Inc. +25.1 (Olmesartan +14.2), Daiichi Sankyo Europe +17.8 (Olmesartan +15.7), ASCA company +14.2 Ranbaxy -12.6, Luitpold -2.6 Currency impact (appreciation of JPY to USD and EUR +46.0, appreciation of JPY to INR +15.0)
SG&A expenses	R&D: +5.1 Currency impact +15.0 (appreciation of JPY to USD, EUR, and INR) Other: +13.5 Currency impact +30.0 (appreciation of JPY to USD, EUR, and INR)
Extraordinary income	Realize gains on sale of non-current assets and investment securities
Extraordinary losses	Loss on business restructuring in EU

2. Currency Rate

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	Q3 YTD		FY2013
	Results	Results	Results	Results	Results	YoY	Forecast
USD/JPY (average)	98.76	98.86	99.39		99.39	+19.38	99.55
EUR/JPY (average)	128.96	130.01	132.24		132.24	+30.06	134.18
INR/JPY (average)	1.71	1.74	1.69		1.69	+0.19	1.66

Depreciation in JPY against USD, EUR, and INR positively affected the FY2013 Q3 YTD results by 61.0 bil yen in net sales and 4.0 bil yen in operating income.

Annual impact of one yen change is estimated to affect the group's FY2013 performance by; USD: net sales 2.0 bil yen, operating income minor / EUR: net sales 0.6 bil yen, operating income minor

3. Segment Information

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			Q3 YTD			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		210.2	+14.6%		218.2	+12.5%		246.2	+10.3%					674.6	74.1	+12.3%
Inter-segment sales		0.4			0.4			0.4						1.1	-0.2	
Net sales	100%	210.6	+14.6%	100%	218.6	+12.6%	100%	246.6	+10.2%				100%	675.8	73.9	+12.3%
Cost of sales	29%	61.9	+29.2%	27%	59.9	+6.7%	31%	75.6	+12.3%				29%	197.3	26.0	+15.2%
Gross Profit	71%	148.7	+9.4%	73%	158.8	+14.9%	69%	171.0	+9.2%				71%	478.5	47.9	+11.1%
SG&A expenses	61%	127.4	+10.0%	57%	125.2	+6.3%	51%	125.3	+2.8%				56%	377.9	22.5	+6.3%
R&D expenses	23%	47.7	+18.3%	19%	42.4	-1.8%	16%	40.2	-6.2%				19%	130.2	4.0	+3.1%
Other expenses	38%	79.8	+5.5%	38%	82.8	+11.0%	35%	85.1	+7.7%				37%	247.7	18.5	+8.1%
Operating Income	10%	21.3	+6.1%	15%	33.6	+65.0%	19%	45.7	+31.7%				15%	100.6	25.4	+33.9%
Non-operating income		2.0			0.7			2.0						4.8	-0.9	
Non-operating expenses		0.5			2.0			-1.1						1.5	-2.4	
Ordinary Income	11%	22.7	+7.8%	15%	32.3	+63.1%	20%	48.9	+35.5%				15%	103.9	26.9	+35.0%
Extraordinary income		1.2			5.8			24.9						31.9	28.9	
Extraordinary losses		11.5			0.6			5.2						17.3	3.9	
Income before income taxes and minority interests	6%	12.5	-42.8%	17%	37.4	+158.0%	28%	68.6	+126.0%				18%	118.5	51.9	+77.8%
Income taxes		2.2			14.9			20.4						37.5	18.1	
Minority interests		-0.4			-0.6			-0.4						-1.4	-1.5	
Net Income	5%	10.6	-22.7%	11%	23.1	+127.7%	20%	48.6	+109.3%				12%	82.3	35.3	+74.9%

Ranbaxy Group

Sales to outside customers		42.3	-28.4%		45.7	-4.1%		44.5	+16.0%					132.4	-12.6	-8.7%
Inter-segment sales		0.3			0.3			0.5						1.1	-0.1	
Net sales	100%	42.6	-28.8%	100%	46.0	-4.0%	100%	45.0	+16.5%				100%	133.6	-12.8	-8.7%
Cost of sales	52%	22.3	+14.5%	52%	23.7	+10.5%	56%	25.1	+24.9%				53%	71.1	10.1	+16.5%
Gross Profit	48%	20.3	-49.6%	48%	22.3	-15.8%	44%	19.9	+7.4%				47%	62.5	-22.8	-26.8%
SG&A expenses	46%	19.5	-26.3%	43%	19.8	-5.2%	44%	19.7	+25.8%				44%	59.0	-4.0	-6.4%
R&D expenses	6%	2.6	+28.2%	6%	2.6	+23.2%	5%	2.1	+7.7%				5%	7.3	1.2	+20.0%
Other expenses	40%	17.0	-30.8%	37%	17.1	-8.5%	39%	17.6	+28.3%				39%	51.7	-5.2	-9.2%
Operating Income	2%	0.8	-94.4%	5%	2.5	-55.3%	0%	0.2	-92.7%				3%	3.5	-18.8	-84.4%
Non-operating income		4.6			0.3			-0.0						4.8	-2.8	
Non-operating expenses		3.4			10.1			6.0						19.4	12.5	
Ordinary Income	5%	2.0	-90.8%	-16%	-7.3	-20.9%	-13%	-5.8	-152.6%				-8%	-11.1	-34.1	-148.2%
Extraordinary income		0.3			0.1			0.0						0.4	0.4	
Extraordinary losses		0.2			2.2			0.7						3.1	3.0	
Income before income taxes and minority interests	5%	2.1	-90.0%	-20%	-9.4	+2.2%	-14%	-6.5	-159.0%				-10%	-13.8	-36.7	-160.0%
Income taxes		-0.5			-3.2			-0.9						-4.7	-12.0	
Minority interests		0.1			0.0			0.0						0.1	0.0	
Net Income	6%	2.5	-83.0%	-13%	-6.2	-10.1%	-12%	-5.6	-175.7%				-7%	-9.2	-24.7	-159.5%

Inter-segment Transactions

Net sales		-0.7			-0.7			-0.9						-2.3		
Cost of sales		-0.4			-0.8			-0.6						-1.8		
Gross Profit		-0.3			0.1			-0.3						-0.5		
SG&A expenses		1.0			1.2			1.2						3.5		
R&D expenses		-0.3			-0.1			-0.1						-0.5		
Other expenses		1.3			1.4			1.4						4.0		
Operating Income		-1.3			-1.2			-1.5						-4.0		
Non-operating income		-0.1			-0.1			-0.1						-0.2		
Non-operating expenses		0.0			0.1			0.0						0.1		
Ordinary Income		-1.4			-1.3			-1.6						-4.3		
Extraordinary income		0			0.2			0.2						0.4		
Extraordinary losses		0.0			-2.1			0.1						-2.0		
Income before income taxes and minority interests		-1.3			1.0			-1.5						-1.9		
Income taxes		0.2			-0.2			-0.3						-0.3		
Minority interests		0.6			-1.7			-2.3						-3.4		
Net Income		-2.1			2.8			1.1						1.8		

4. Sales by Business Units

	FY2013			Q1			Q2			Q3			Q4			Q3 YTD			
	Plan(May)	Plan(Jan)	±	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
JPY Bn																			
Consolidated Net Sales	1,080.0	1,110.0	30.0	252.5	+4.1%	23%	263.9	+9.3%	24%	290.7	+11.2%	26%				807.1	61.4	+8.2%	73%
Japan Company (domestic sales)	480.0	485.0	5.0	106.6	+8.6%	22%	115.0	+7.6%	24%	136.0	+9.0%	28%				357.6	27.8	+8.4%	74%
Olmotec	81.0	83.0	2.0	16.6	-8.9%	20%	20.9	+8.4%	25%	22.9	+9.4%	28%				60.4	2.0	+3.4%	73%
Rezaltas	24.0	21.0	-3.0	4.3	+9.6%	21%	4.6	+12.2%	22%	5.2	+13.5%	25%				14.1	1.5	+11.9%	67%
Calblock	9.0	9.0	0.0	2.4	-11.1%	27%	2.4	-14.5%	26%	2.3	-18.2%	26%				7.1	-1.2	-14.6%	79%
Loxonin	61.0	61.0	0.0	14.9	+5.8%	25%	15.7	+0.6%	26%	16.2	-0.1%	27%				46.8	0.9	+1.9%	77%
Cravit	36.0	35.0	-1.0	7.6	-5.4%	22%	8.1	-4.0%	23%	10.2	-4.4%	29%				25.9	-1.2	-4.6%	74%
Nexium	38.0	52.0	14.0	10.9	+562.1%	21%	13.1	+375.9%	25%	16.2	+95.3%	31%				40.2	27.5	+216.8%	77%
Memary	36.0	34.0	-2.0	6.6	+28.7%	19%	7.8	+38.2%	23%	9.5	+43.9%	28%				23.9	6.5	+37.5%	70%
Mevalotin	23.0	22.0	-1.0	5.2	-20.5%	24%	5.9	-12.5%	27%	5.9	-10.0%	27%				17.0	-2.8	-14.3%	77%
Artist	22.0	22.0	0.0	5.4	-3.4%	25%	5.7	+0.6%	26%	6.0	+3.6%	28%				17.1	0.1	+0.3%	78%
Omnipaque	19.0	19.0	0.0	4.7	-4.0%	25%	5.2	-0.7%	28%	5.6	+4.3%	29%				15.5	0.0	+0.0%	82%
Urief	12.0	12.0	0.0	2.7	+0.1%	22%	2.9	+4.2%	24%	3.2	+9.4%	27%				8.8	0.4	+4.7%	73%
Inavir	10.0	10.0	0.0	0.3	-38.8%	3%	0.0	-90.6%	0%	1.8	-15.2%	18%				2.0	-0.5	-20.9%	20%
Ranmark	6.0	7.0	1.0	1.6	+162.8%	22%	1.9	+68.0%	27%	2.4	+76.8%	34%				5.8	2.8	+90.3%	83%
Vaccines	not disclosed	not disclosed		8.0	+53.9%	-	7.1	-12.3%	-	12.1	+2.1%	-				27.2	2.1	+8.2%	-
Daichi Sankyo Espha products	not disclosed	not disclosed		2.9	+3.6%	-	3.0	+13.2%	-	3.8	+27.3%	-				9.8	1.3	+15.0%	-
Daiichi Sankyo Healthcare (OTC)	48.0	48.0	0.0	9.8	-4.6%	20%	13.1	+2.5%	27%	14.1	-2.8%	29%				37.0	-0.6	-1.5%	77%
Daiichi Sankyo, Inc. (US)	150.0	163.0	13.0	46.6	+29.7%	29%	39.9	+22.2%	25%	44.6	+19.3%	27%				131.1	25.1	+23.7%	80%
Olmesartan	86.0	103.0	17.0	30.7	+28.4%	30%	26.1	+20.0%	25%	28.7	+11.8%	28%				85.5	14.2	+19.9%	83%
Benicar/Benicar HCT	67.0	79.0	12.0	23.8	+26.1%	30%	20.2	+20.6%	26%	21.6	+7.0%	27%				65.6	9.8	+17.5%	83%
Azor	12.0	15.0	3.0	4.6	+31.6%	31%	3.8	+9.3%	25%	4.4	+15.6%	29%				12.8	2.0	+18.8%	85%
Tribenzor	6.0	8.0	2.0	2.3	+49.3%	29%	2.1	+39.1%	26%	2.7	+62.6%	33%				7.1	2.4	+50.6%	89%
Welchol	46.0	43.0	-3.0	11.4	+37.4%	26%	9.6	+33.8%	22%	11.7	+39.8%	27%				32.7	8.8	+37.2%	76%
Effient (alliance revenue)	not disclosed	not disclosed		4.0	+65.0%	-	3.6	+55.1%	-	3.8	+38.8%	-				11.4	3.9	+52.3%	-
Luitpold Pharmaceuticals, Inc. (US)	40.0	40.0	0.0	8.1	-28.7%	20%	10.2	+32.0%	25%	9.6	-15.6%	24%				27.8	-2.6	-8.4%	70%
Venofor	19.0	26.0	7.0	4.9	-27.7%	19%	6.8	+76.5%	26%	6.4	-23.0%	25%				18.1	-0.9	-4.5%	70%
Daiichi Sankyo Europe GmbH	73.0	78.0	5.0	19.0	+36.8%	24%	21.4	+41.8%	27%	23.3	+37.6%	30%				63.7	17.8	+38.8%	82%
Olmesartan	56.0	60.0	4.0	14.4	+45.0%	24%	16.8	+48.0%	28%	18.7	+44.7%	31%				49.8	15.7	+45.9%	83%
Olmetec/Olmetec Plus	37.0	41.0	4.0	9.8	+52.4%	24%	11.6	+42.6%	28%	12.7	+47.8%	31%				34.1	10.9	+47.3%	83%
Sevikar	11.0	12.0	1.0	3.0	+19.5%	25%	3.1	+32.6%	26%	4.0	+30.2%	33%				10.0	2.2	+27.5%	84%
Sevikar HCT	7.0	6.0	-1.0	1.6	+62.2%	26%	2.1	+136.2%	35%	2.0	+58.8%	34%				5.7	2.6	+82.0%	95%
Effient (alliance revenue)	not disclosed	not disclosed		1.2	+30.3%	-	1.1	+23.1%	-	1.2	+32.5%	-				3.5	0.8	+28.7%	-

		Q1 Results			Q2 YTD Results			Q3 YTD Results			Q4 YTD Results			FY2013 Forecast			
		USD	EUR	INR	USD	EUR	INR	USD	EUR	INR	USD	EUR	INR	USD	EUR	INR	
Currency rate YoY comparison	FY2012	80.21	102.91	1.59	79.42	100.64	1.54	80.01	102.18	1.50				5/13	95.00	125.00	1.75
	FY2013	98.76	128.96	1.71	98.86	130.01	1.74	99.39	132.24	1.69				10/31	96.93	130.01	1.66
	YoY	18.55	26.05	0.12	19.44	29.37	0.20	19.38	30.06	0.19				1/31	99.55	134.18	1.66
Currency rate impact (Bn yen)	Nes Sales	about +18.0 Bn yen			about +41.0 Bn yen			about +61.0 Bn yen									
	Operating Income	about +0.5 Bn yen			about +1.0 Bn yen			about +4.0 Bn yen									

4. Sales by Business Units

	FY2013			Q1			Q2			Q3			Q4			Q3 YTD			
	Plan(May)	Plan(Jan)	±	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
Asia, South and Central America (ASCA)	46.0	46.0	0.0	11.2	+58.5%	24%	12.7	+57.2%	28%	13.7	+66.2%	30%				37.6	14.2	+60.8%	82%
Daiichi Sankyo China	not disclosed	not disclosed		4.7	+77.3%	-	4.9	+62.6%	-	5.3	+71.4%	-				15.0	6.2	+70.2%	-
Daiichi Sankyo Taiwan	not disclosed	not disclosed		1.1	+40.0%	-	1.1	+37.5%	-	1.1	+37.6%	-				3.3	0.9	+38.4%	-
Daiichi Sankyo Korea	not disclosed	not disclosed		1.8	+44.6%	-	2.2	+79.1%	-	2.7	+102.1%	-				6.6	2.9	+75.8%	-
Daiichi Sankyo (Thailand)	not disclosed	not disclosed		0.4	+46.7%	-	0.4	+36.5%	-	0.8	+107.1%	-				1.6	0.6	+66.7%	-
Daiichi Sankyo Brasil Farmacêutica	not disclosed	not disclosed		1.7	+40.8%	-	2.0	+72.5%	-	2.0	+100.5%	-				5.7	2.3	+69.3%	-
Daiichi Sankyo Venezuela	not disclosed	not disclosed		1.3	+48.4%	-	1.8	+22.7%	-	1.5	-1.5%	-				4.5	0.7	+18.8%	-
Daiichi Sankyo Mexico S.A. de C.V	not disclosed	not disclosed		0.2	+188.6%	-	0.2	+59.5%	-	0.2	+93.9%	-				0.6	0.3	+103.5%	-
Ranbaxy Group*	217.0	224.0	7.0	42.3	-28.4%	-	45.7	-4.1%	-	44.5	+16.0%	-				132.4	-12.6	-8.7%	59%
Others	26.0	26.0	0.0	8.9	+30.3%	34%	6.0	-44.5%	23%	5.0	-50.0%	19%				19.9	-7.7	-28.0%	77%

* Since Ranbaxy Group will change their fiscal year-ends from December to March, their FY2013 financial results will be for 15 months.

[Reference] Sales in Local Currency

	FY2013			Q1			Q2			Q3			Q4			Q3 YTD			
	Plan(May)	Plan(Jan)	±	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
USD Mn																			
Daiichi Sankyo, Inc. (US)	1,579	1,682	103	472	+5.3%	28%	403.0	-3.0%	24%	444.0	-3.6%	26%				1,319	-5	-0.4%	78%
Olmesartan	905	1,063	157	311	+4.3%	29%	263	-4.7%	25%	286	-9.7%	27%				860	-31	-3.5%	81%
Benicar/Benicar HCT	705	815	110	241	+2.4%	30%	204	-4.3%	25%	215	-13.7%	26%				660	-38	-5.4%	81%
Azor	126	155	28	47	+6.9%	30%	38	-13.2%	25%	44	-6.6%	28%				129	-6	-4.4%	83%
Tribenzor	63	83	19	23	+21.3%	28%	21	+10.5%	26%	26	+31.6%	32%				71	12	+21.3%	86%
Welchol	484	444	-41	115	+11.6%	26%	97	+6.2%	22%	116	+13.0%	26%				329	31	+10.4%	74%
Effient (alliance revenue)	not disclosed	not disclosed		41	+34.0%	-	37	+23.2%	-	38	+12.0%	-				115	21	+22.6%	-
USD Mn																			
Luitpold Pharmaceuticals, Inc. (US)	421	413	-8	82	-42.1%	20%	103.0	+4.4%	25%	95.0	-31.9%	23%				280	-100	-26.3%	68%
Venofer	200	268	68	50	-41.2%	19%	68	+39.2%	26%	64	-38.0%	24%				182	-55	-23.2%	68%
EUR Mn																			
Daiichi Sankyo Europe GmbH	584	600	16	147	+9.2%	25%	163.0	+6.8%	27%	171.0	+6.0%	29%				482	32	+7.2%	80%
Olmesartan	448	462	14	111	+15.7%	24%	128	+11.6%	28%	137	+11.4%	30%				377	43	+12.7%	82%
Olmetec/Olmetec Plus	296	315	19	76	+21.6%	24%	89	+7.7%	28%	93	+13.9%	30%				258	31	+13.8%	82%
Sevikar	88	92	4	23	-4.6%	25%	23	-0.5%	25%	29	+0.4%	32%				76	-1	-1.5%	82%
Sevikar HCT	56	46	-10	12	+29.4%	27%	16	+77.5%	35%	15	+21.6%	32%				43	12	+40.7%	94%
Effient (alliance revenue)	not disclosed	not disclosed		9	+4.0%	-	8	-7.5%	-	9	+2.2%	-				27	0	-0.5%	-
INR Bn																			
Ranbaxy Group*	120	135	15	25	-33.5%	-	26.0	-19.7%	-	28.0	+1.5%	-				78	-18	-19.0%	58%

* Since Ranbaxy Group will change their fiscal year-ends from December to March, their FY2013 financial results will be for 15 months.

5. Sales of Global Products

	FY2013			Q1			Q2			Q3			Q4			Q3 YTD				
	Plan(May)	Plan(Jan)	±	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan	
JPY Bn																				
Olmesartan	269.0	289.0	20.0	71.4	+19.0%	25%	74.6	+22.7%	26%	81.9	+19.8%	28%				227.9	38.8	+20.5%	79%	
Olmetec (JPN)	81.0	83.0	2.0	16.6	-8.9%	20%	20.9	+8.4%	25%	22.9	+9.4%	28%				60.4	2.0	+3.4%	73%	
Rezaltas (JPN)	24.0	21.0	-3.0	4.3	+9.6%	21%	4.6	+12.2%	22%	5.2	+13.5%	25%				14.1	1.5	+11.9%	67%	
Benicar/Benicar HCT (US)	67.0	79.0	12.0	23.8	+26.1%	30%	20.2	+20.6%	26%	21.6	+7.0%	27%				65.6	9.8	+17.5%	83%	
Azor (US)	12.0	15.0	3.0	4.6	+31.6%	31%	3.8	+9.3%	25%	4.4	+15.6%	29%				12.8	2.0	+18.8%	85%	
Tribenzor (US)	6.0	8.0	2.0	2.3	+49.3%	29%	2.1	+39.1%	26%	2.7	+62.6%	33%				7.1	2.4	+50.6%	89%	
Olmetec/Olmetec Plus (EU)	37.0	41.0	4.0	9.8	+52.4%	24%	11.6	+42.6%	28%	12.7	+47.8%	31%				34.1	10.9	+47.3%	83%	
Sevikar (EU)	11.0	12.0	1.0	3.0	+19.5%	25%	3.1	+32.6%	26%	4.0	+30.2%	33%				10.0	2.2	+27.5%	84%	
Sevikar HCT (EU)	7.0	6.0	-1.0	1.6	+62.2%	26%	2.1	+136.2%	35%	2.0	+58.8%	34%				5.7	2.6	+82.0%	95%	
Other subsidiaries, export, etc	24.0	24.0	0.0	5.4	+35.4%	23%	6.2	+44.0%	26%	6.5	+49.9%	27%				18.0	5.4	+43.3%	75%	
Prasugrel	not disclosed	not disclosed		5.2	+55.6%	-	4.7	+46.3%	-	5.0	+37.2%	-				14.9	4.7	+46.0%	-	
Effient alliance revenue (US)	not disclosed	not disclosed		4.0	+65.0%	-	3.6	+55.1%	-	3.8	+38.8%	-				11.4	3.9	+52.3%	-	
Effient alliance revenue (EU)	not disclosed	not disclosed		1.2	+30.3%	-	1.1	+23.1%	-	1.2	+32.5%	-				3.5	0.8	+28.7%	-	

6. Number of Employees

	Mar 2013 Results	Jun 2013 Results	Sep 2013 Results	Dec 2013 Results	Mar 2014 Results
Total Number of Employees	32,229	32,402	32,193	32,001	
Japan	9,251	9,379	9,317	9,302	
* Overseas	22,978	23,023	22,876	22,699	
Daiichi Sankyo Group	17,528	17,716	17,549	17,451	
* Ranbaxy Group	14,701	14,686	14,644	14,550	

* For overseas subsidiaries with different fiscal year-ends, numbers as of September-end are shown in the December-end columns

MEMO

(This page is intentionally left blank)

7. Consolidated Balance Sheets

(Billions of yen)

	Mar 2013	Dec 2013	QoQ	Notes
ASSETS				
Current assets				
Cash and time deposits	161.0	183.3	22.3	PBT +102.8 Bn, Depreciation and amortization +40.4 Bn, Increase in loans payable +86.7 Bn Proceeds from issuance of bonds +39.9 Bn, Settlement expenses paid -49.8 Bn Income taxes paid -46.0 Bn, Dividends paid -42.2 Bn Net purchase and acquisitions of proceeds from sales of non-current assets -25.4 Bn
Trade notes and accounts receivable	238.5	269.3	30.8	
Marketable securities	211.3	277.5	66.2	
Inventories	174.4	189.6	15.2	
Deferred tax assets	111.1	111.1	0.0	
Other current assets	50.0	59.7	9.7	
Allowance for doubtful accounts	-2.7	-3.2	-0.5	
Total current assets	943.6	1,087.2	143.6	
Non-current assets				
Property, plant and equipment				
Buildings and structures, net	138.3	140.7	2.4	
Machinery, equipment and vehicles, net	63.5	63.1	-0.4	
Land	35.8	36.2	0.4	
Construction in progress	47.9	59.4	11.5	
Other, net	18.0	21.6	3.6	
Total property, plant and equipment	303.4	321.0	17.5	Newly added: Daiichi Sankyo +13.4 Bn
Intangible assets				
Goodwill, net	73.5	70.9	-2.6	
Other intangible assets, net	149.9	152.8	2.9	
Total intangible assets	223.5	223.7	0.3	
Investments and other assets				
Investment securities	129.2	121.6	-7.6	
Deferred tax assets	32.5	40.5	8.0	
Other	12.1	24.6	12.4	
Allowance for doubtful accounts	-0.3	-0.4	0.0	
Total investments and other assets	173.5	186.3	12.8	
Total non-current assets	700.4	731.0	30.6	
Total assets	1,644.1	1,818.3	174.2	

(Billions of yen)

	Mar 2013	Dec 2013	QoQ	Notes
LIABILITIES				
Current liabilities				
Trade notes and accounts payable	59.8	69.0	9.2	
Short-term loans payable	66.1	79.5	13.4	Daiichi Sankyo +10.0 Bn (Transfer from long-term liabilities +30.0 Bn, Payment -20.0 Bn)
Current portion of bonds	0.0	60.0	60.0	Daiichi Sankyo +60.0 Bn (Transfer from long-term liabilities +60.0 Bn)
Income taxes payable	23.2	11.9	-11.3	
Provision for restructuring loss	0.0	8.8	8.8	
Allowance for sales returns	0.6	4.5	3.9	
Allowance for sales rebates	2.0	3.4	1.4	
Provision for settlement expenses	43.7	0.0	-43.7	Ranbaxy -43.7 Bn
Provision for environment measures	1.3	0.0	-1.3	
Accrued expenses	111.7	104.7	-7.0	
Other current liabilities	127.7	132.3	4.6	
Total current liabilities	436.1	473.9	37.8	
Long-term liabilities				
Bonds payable	107.9	88.5	-19.4	Daiichi Sankyo -20.0 Bn (Issuance +40.0 Bn, Transfer to current liabilities -60.0 Bn)
Long-term loans payable	93.0	174.2	81.2	Daiichi Sankyo +71.0 Bn (Loan +101.0 Bn, Transfer to current liabilities -30.0 Bn), Ranbaxy +10.2 Bn
Deferred tax liabilities	45.1	47.0	1.9	
Accrued employees' severance and retirement benefits	13.9	8.2	-5.6	
Accrued directors' severance and retirement benefits	0.2	0.3	0.0	
Other long-term liabilities	32.1	33.2	1.1	
Total long-term liabilities	292.2	351.4	59.1	
Total liabilities	728.3	825.3	97.0	
NET ASSETS				
Shareholders' equity				
Common stock	50.0	50.0	0.0	
Capital surplus	105.2	105.2	0.0	
Retained earnings	766.7	799.4	32.6	Net income +74.9 Bn, Dividends paid -42.2 Bn
Treasury stock, at cost	-14.5	-14.4	0.0	
Total shareholders' equity	907.5	940.2	32.7	
Accumulated other comprehensive income				
Net unrealized gain on investment securities	34.2	33.6	-0.7	
Deferred gains or losses on hedges	0.9	1.0	0.1	
Foreign currency translation adjustments	-60.0	-13.1	46.9	Increase in net assets of overseas subsidiaries on a JPY basis +46.9 Bn
Total accumulated other comprehensive income	-24.8	21.5	46.3	
Subscription rights to shares	4.1	4.3	0.2	
Minority interests	29.0	27.0	-2.0	Ranbaxy -0.8 Bn, Kitasato Daiichi Sankyo Vaccine (KDSV) -1.4 Bn
Total net assets	915.7	993.0	77.2	
Total liabilities and net assets	1,644.1	1,818.3	174.2	

8. Consolidated Statements of Cash Flows

(Billions of yen)

	FY2012 Q3 Results	FY2013 Q3 Results	YoY	Notes
Cash flows from operating activities				
Income before income taxes and minority interests	85.4	102.8	17.4	
Depreciation and amortization of goodwill	38.7	40.4	1.7	
Increase/decrease in trade receivable and payable	-32.6	-37.1	-4.4	
Other, net	12.1	-70.2	-82.2	FY2013: Ranbaxy payment for settlement expenses (-49.8)
Income taxes paid	-22.4	-46.0	-23.7	
Net cash provided by operating activities	81.1	-10.0	-91.1	
Cash flows from investing activities				
Net (increase) decrease in short-term investments	-43.8	-82.3	-38.4	
(Acquisition of) proceeds from sales of non-current assets	-62.2	-25.4	36.8	
Other, net	19.5	8.4	-11.1	
Net cash used in investing activities	-86.5	-99.3	-12.7	
Cash flows from financing activities				
Net increase (decrease) in loans payable	-24.3	86.7	111.0	
Proceeds from issuance of bonds	—	39.9	39.9	
Dividends paid	-42.3	-42.2	0.0	
Other, net	-0.1	-0.8	-0.7	
Net cash used in financing activities	-66.6	83.5	150.2	
Effect of exchange rate changes on cash and cash equivalents	3.6	18.3	14.7	
Net increase (decrease) in cash and cash equivalents	-68.4	-7.4	61.0	
Cash and cash equivalents, beginning of period	212.7	190.9	-21.8	
Cash and cash equivalents, at end of period	144.3	183.5	39.2	

9. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance
Japan Company (domestic sales)					
Olmotec	olmesartan	antihypertensive	2004	Daiichi Sankyo	
Rezaltas	olmesartan / azelnidipine	antihypertensive	2010	Daiichi Sankyo	
Calblock	azelnidipine	antihypertensive	2003	Ube Industries	
Loxonin			1986	Daiichi Sankyo	
Loxonin Poultice			2006	Lead Chemical	
Loxonin Tape	loxoprofen	analgesic and anti-inflammatory	2008	Lead Chemical	
Loxonin Gel			2010	Daiichi Sankyo	
Cravit	levofloxacin	antibacterial	1993	Daiichi Sankyo	
Nexium	esomeprazole	proton pump inhibitor	2011	AstraZeneca	AstraZeneca
Memory	memantine	treatment for Alzheimer's Disease	2011	Merz	
Mevalotin	pravastatin	antihyperlipidemic	1989	Daiichi Sankyo	
Artist	carvedilol	antihypertensive	1993	Roche	
Omnipaque	iohexol	contrast medium	1987	GE Healthcare	
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei
Inavir	laninamivir	anti-influenza	2010	Daiichi Sankyo	
Ranmark	denosumab	anti-RANKL antibody	2012	Amgen	AstraZeneca
Pralia	denosumab	anti-RANKL antibody	2013	Amgen	
Tenelia	teneligliptin	type 2 diabetes	2012	Mitsubishi Tanabe	Mitsubishi Tanabe
Daiichi Sankyo, Inc. (US)					
Olmesartan					
Benicar	olmesartan		2002		
Benicar HCT	olmesartan / hydrochlorothiazide	antihypertensive	2003	Daiichi Sankyo	
Azor	olmesartan / amlodipine		2007		
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010		
Welchol	colesevelam	antihyperlipidemic / type 2 diabetes	2000	Genzyme	
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly
Luitpold Pharmaceuticals, Inc. (US)					
Venofer	iron sucrose injection	iron deficiency anemia	2000	Vifor Pharma	Fresenius
Daiichi Sankyo Europe GmbH					
Olmesartan					
Olmotec	olmesartan		2002		
Olmotec Plus	olmesartan / hydrochlorothiazide	antihypertensive	2005	Daiichi Sankyo	Menarini Pfizer Nycomed
Sevikar	olmesartan / amlodipine		2009		
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010		
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly

◆ **Launched/Approved**

Project code Number	Generic Name	Class	Target indication	Stage	Remarks
AMG 162	denosumab	Anti-RANKL antibody	Osteoporosis	JP Launched	Launched in Jun 2013
<p>The fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation. Launched in Japan in April 2012 as treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors, and in June 2013 as treatment for osteoporosis.</p>					
CS-8958	laninamivir	Neuraminidase inhibitor	Anti-influenza, prophylactic	JP Approved/ Launched	Approved/Launched in Dec 2013
<p>The long-acting neuraminidase inhibitor developed and produced by Daiichi Sankyo. This is an inhalant that will act directly on the pulmonary and tracheal sites of infection. Launched in Japan in October 2010 as treatment for influenza A and influenza B viruses.</p>					

◆ **Filed**

Project code Number	Generic Name	Class	Target indication	Stage	Remarks
CS-747	prasugrel	Anti-platelet agent	Ischemic heart disease undergoing PCI	JP Filed	Filed in Jun 2013
<p>The oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries, Ltd. Prasugrel helps keep blood platelets from clumping together and developing a blockage in an artery</p>					
AMG 162	denosumab	Anti-RANKL antibody	Giant cell tumor of bone	JP Filed	Filed in Aug 2013
<p>Application to manufacture and market RANMARK®. Denosumab obtained orphan drug designation for GCTB indication in June 2013</p>					
DU-176b	edoxaban	Factor Xa inhibitor	Atrial Fibrillation (AF)	JP/US/EU Filed	Filed in Dec 2013(JP) Filed in Jan 2014(US/EU)
			Venous thromboembolism (VTE)	JP/US/EU Filed	Filed in Dec 2013(JP) Filed in Jan 2014(US/EU)
<p>The once daily oral anti coagulant (Fxa inhibitor) discovered by Daiichi Sankyo. Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Launched in Japan in July 2011 as the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery.</p>					

◆ Under development (Phase1-3)

Project code Number	Generic Name	Class	Target indication	Stage	Remarks	
CS-747	prasugrel	Anti-platelet agent	Ischemic Stroke	JP	P3	Study to be completed in FY2014
			Sickle cell disease	US		
AMG 162	denosumab	Anti-RANKL antibody	Breast cancer adjuvant	JP	P3	
			Rheumatoid arthritis	JP	P3	
DR-3355	levofloxacin	New quinolone	Anti-infection	JP	P3	
ARQ 197	tivantinib	MET inhibitor	Hepatocellular cancer	US/EU	P3	
DE-766	nimotuzumab	Anti-EGFR antibody	Gastric cancer	JP	P3	
			Non small cell lung cancer	JP	P3	
			Esophageal cancer	JP	P1	
DS-7113	hydromorphone	opioid mu-receptor agonist	Cancer pain	JP	P3	
CS-3150	-	MR antagonist	Hypertension	JP	P2	
			Diabetic nephropathy	JP	P2	
U3-1287	patritumab	Anti-HER3 antibody	Non small cell lung cancer	US/EU	P2	
			Non small cell lung cancer	JP	P1	
			Breast cancer	US	P2	
			Breast cancer	JP	P1	
PLX4032	vemurafenib	BRAF inhibitor	Thyroid cancer	US/EU	P2	
PLX3397	-	Fms/Kit/Flt3-ITD inhibitor	Hodgkin lymphoma	US	P2	
			Acute myeloid leukemia	US	P2	
			Glioblastoma	US	P2	
			Prostate Cancer	US	P2	
DS-5565	-	$\alpha 2\delta$ ligand	Chronic pain	Global	P2	
SUN13837	-	Modulator of bFGF signaling system	Spinal cord injury	US/EU	P2	
ASB17061	-	Chymase inhibitor	Atopic Dermatitis	US	P2	
CS-8958	laninamivir	Neuraminidase inhibitor	Anti-influenza	US/EU	P2	

◆ Under development (Phase1-3)

Project code Number	Generic Name	Class	Target indication	Stage	Remarks
DS-7309	-	Glucokinase activator	Diabetes	-	P1
DS-8500	-	GPR119 agonist	Diabetes	-	P1
DS-1442	-	CETP inhibitor	Dyslipidemia	-	P1
DS-1040	-	TAF1a inhibitor	Acute ischemic stroke	-	P1
U3-1565	-	Anti-HB-EGF antibody	Solid cancer	US/JP	P1
DS-2248	-	HSP90 inhibitor	Solid cancer	US	P1
DS-7423	-	PI3K/mTOR inhibitor	Solid cancer	US/JP	P1
DS-3078	-	mTOR inhibitor	Solid cancer, lymphoma	US/EU	P1
DS-3032	-	MDM2 inhibitor	Solid cancer, lymphoma	US	P1
PLX7486	-	Fms/Trk inhibitor	Solid cancer	US	P1
DS-8895	-	Anti-EPHA2 antibody	Solid cancer	JP	P1
DS-8587	-	Topoisomerase inhibitor	Anti-bacterial	-	P1
CS-4771	-	TLR4 inhibitor	Anti-sepsis	-	P1
PLX5622	-	FMS kinase inhibitor	Rheumatoid arthritis	-	P1
CS-0777	-	S1P receptor modulator	Immunomodulator	-	P1
DS-1093	-	HIF-PH inhibitor	Anemia of chronic kidney disease	-	P1

◆ Change of stage from announcement in Oct 2013




Project code Number	Generic Name	Class	Target indication	Stage	
CS-8958	laninamivir	Neuraminidase inhibitor	Anti-influenza, prophylactic	JP	Approved/ Launched
DU-176b	edoxaban	Factor Xa inhibitor	Atrial Fibrillation (AF)	JP/US/EU	Filed
			Venous thromboembolism (VTE)	JP/US/EU	Filed
AMG 162	denosumab	Anti-RANKL antibody	Rheumatoid arthritis	JP	P3
DS-7113	hydromorphone	opioid mu-receptor agonist	Cancer pain	JP	P3
DS-8895	-	Anti-EPHA2 antibody	Solid cancer	JP	P1

◆ Discontinue

Project code Number	Generic Name	Class	Target indication	Stage	
ARQ 197	tivantinib	MET inhibitor	Colorectal cancer	US/EU	P2
<Reason for discontinue> Daiichi Sankyo decided to discontinue the development of ARQ 197 after reviewing its clinical studies results.					

◆ Major R&D Pipeline Table

As of January, 2014

Therapeutic Area	Phase1	Phase2	Phase3	Application
Cardiovascular - Metabolics	<p>DS-7309 (Anti-diabetes / Glucokinase activator)</p> <p>DS-8500 (Anti-diabetes / GPR119 agonist)</p> <p>DS-1442 (Dyslipidemia / CETP inhibitor)</p> <p>DS-1040 (Acute ischemic stroke / TAF1a inhibitor)</p>	<p>CS-3150 (JP) (Anti-hypertension / Diabetic nephropathy / MR antagonist)</p>	 <p>CS-747 (JP) (prasugrel / ischemic stroke / anti-platelet agent)</p> <p>CS-747 (US) (prasugrel / sickle cell disease / anti-platelet agent)</p>	<p>DU-176b (Global) (edoxaban / AF / oral factor Xa inhibitor)</p> <p>DU-176b (Global) (edoxaban / VTE / oral factor Xa inhibitor)</p> <p>CS-747 (JP) (prasugrel / PCI / anti-platelet agent)</p>
Oncology	<p>U3-1565 (US/JP) (Anti-HB-EGF antibody)</p> <p>DS-2248 (US) (HSP90 inhibitor)</p> <p>DS-7423 (US/JP) (PI3K/mTOR inhibitor)</p> <p>DS-3078 (US/EU) (mTOR inhibitor)</p> <p>DS-3032 (US) (MDM2 inhibitor)</p> <p>PLX7486 (US) (Fms/Trk inhibitor)</p> <p>DS-8895 (JP) (Anti-EPHA2 antibody)</p>	<p>U3-1287 (US/EU) (patritumab / anti-HER3 antibody)</p> <p>PLX4032 (US/EU) (vemurafenib / BRAF inhibitor)</p> <p>PLX3397 (US) (Fms/Kit/Flt3-ITD inhibitor)</p>	<p>ARQ 197 (US/EU) (tivantinib / HCC / MET inhibitor)</p> <p>AMG 162 (JP) (denosumab / breast cancer adjuvant / anti-RANKL antibody)</p> <p>DE-766 (JP) (nimotuzumab / NSCLC / anti-EGFR antibody)</p> <p>DE-766 (JP) (nimotuzumab / Gastric cancer / anti-EGFR antibody)</p>	<p>AMG 162 (JP) (denosumab / Giant cell tumor / anti-RANKL antibody)</p>
Others	<p>DS-8587 (Anti-bacterial / Topoisomerase inhibitor)</p> <p>CS-4771 (Anti-sepsis / TLR4 inhibitor)</p> <p>PLX5622 (Rheumatoid arthritis / FMS kinase inhibitor)</p> <p>CS-0777 (Immunomodulator / S1P receptor modulator)</p> <p>DS-1093 (Anemia of chronic kidney disease/HIF-PH inhibitor)</p>	 <p>DS-5565 (Global) (Chronic pain / $\alpha 2\delta$ ligand)</p> <p>SUN13837 (US/EU) (Spinal cord injury / Modulator of bFGF signaling system)</p> <p>ASB17061 (US) (Atopic Dermatitis / chymase inhibitor)</p> <p>CS-8958 (US/EU) (laninamivir / anti-influenza / Outlicensing with Biota)</p> 	<p>AMG 162 (JP) (denosumab / Rheumatoid arthritis / anti-RANKL antibody)</p> <p>DR-3355 (JP) (levofloxacin / anti-infection / New quinolone)</p> <p>DS-7113 (hydromorphone / Cancer pain/ opioid mu-receptor agonist)</p>	<p>CS-8958 (JP) (laninamivir / anti-influenza, prophylactic / Neuraminidase inhibitor)</p>

Cardiovascular-Metabolics

[Project after Phase 2]

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DU-176b	edoxaban	Oral	Factor Xa inhibitor	Atrial fibrillation (AF) Venous thromboembolism (VTE)	Daiichi Sankyo	Lixiana(JP) TBC(EU) SAVAYSA(US, Planned)
<ul style="list-style-type: none"> • An oral anticoagulant that specifically, reversibly and directly inhibits Xa factor playing an important role in the process when blood coagulates. • An oral factor Xa inhibitor, possible once daily regimen with high oral absorption, confirmed by clinical trials. • No severe hepatotoxicity signals in pre-clinical and clinical trials. • [JP] Launched for the prevention of VTE after major orthopedic surgery in July-2011. Brand name: Lixiana • Hokusai-VTE(VTE) P3 studies was presented at ESC 2013. • ENGAGE AF-TIMI 48(AF) P3 study was presented at AHA 2013. • NDA for AF/VTE indication Filed. (JPN: Dec, 2013, US/EU: Jan, 2014) 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-747	prasugrel	Oral	Anti-platelet agent	Ischemic heart disease undergoing PCI Ischemic stroke Sickle cell disease	Daiichi Sankyo Ube Industries	Effient (US, Asia) Efient (EU)
<ul style="list-style-type: none"> • Inhibition of platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. • Co-development with Eli Lilly in the US and EU, development by Daiichi Sankyo in Japan. • [EU] Approved in Feb-2009 for ACS-PCI. Brand name: Efient • [US] Approved in Jul-2009 for ACS-PCI. Brand name: Effient, P3 study in pediatric sickle cell disease patients is on-going. • [JP] Filed in Jun-2013 for the ischemic heart disease undergoing PCI. P3 studies for ischemic stroke are on-going. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-3150	-	Oral	MR antagonist	Hypertension Diabetic nephropathy	Exelixis	TBD
<ul style="list-style-type: none"> • Inhibitor of MR (mineralocorticoid receptor) binding to aldosterone to show antihypertensive and organ-protective effect. • P2 study in essential hypertension was completed and the P2 study in diabetes with albuminuria is ongoing in Japan. 						

Oncology

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
ARQ 197	tivantinib	Oral	Met inhibitor	Hepatocellular cancer	ArQule	TBD
<ul style="list-style-type: none"> • Met has multiple roles in intracellular signal transductions such as cancer cell motility, proliferation, angiogenesis, invasion, and apoptosis induction. • Variations of c-Met are shown in gastric, HCC, head and neck cancer, and high expression of c-met are shown in colon, HCC, pancreatic, prostate, breast cancer, etc. • A P3 clinical study for HCC was started in Jan-2013. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DE-766	nimotuzumab	Injection	Anti-EGFR antibody	Gastric cancer Non small cell lung cancer Esophageal cancer	InnoMab	TBD
<ul style="list-style-type: none"> • A humanized monoclonal antibody against Epidermal Growth Factor Receptor(EGFR). • Expected to be a best in class EGFR antibody, safety against the skin toxicity and the efficacy comparable to the other EGFR antibodies. • P3 in Japan for NSCLC started in March 2013, that for Gastric cancer started in April 2013. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
U3-1287	patritumab	Injection	Anti-HER3 antibody	Non small cell lung cancer Breast cancer	Daiichi Sankyo (U3 Pharma)	TBD
<ul style="list-style-type: none"> • HER3 is one of the member of the Epidermal Growth Factor Receptor(EGFR) family of proteins. • HER3 is overexpressed in many tumors of epithelial origin and HER2/HER3 dimers and EGFR/HER3 dimers are more potent to induce cell proliferation than homodimers of HER2 or EGFR. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
PLX4032	vemurafenib	Oral	BRAF inhibitor	Thyroid cancer	Daiichi Sankyo (Plexxikon)	Zelboraf
<ul style="list-style-type: none"> • Plexxikon discovered vemurafenib, and since 2006, has been co-developing it with partner, Roche. • Personalized treatment for patients with unresectable (inoperable) or metastatic melanoma with a BRAF V600E mutation as detected by an FDA-approved test. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
PLX3397	-	Oral	Fms/Kit/Flt3-ITD inhibitor	Hodgkin lymphoma Acute myeloid leukemia Glioblastoma Prostate Cancer	Daiichi Sankyo (Plexxikon)	TBD
<ul style="list-style-type: none"> • Plexxikon discovered PLX3397. • Clinical studies are on-going for several types of cancer. 						

Others

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
AMG 162	denosumab	Injection	Anti-RANKL antibody	Breast cancer adjuvant Rheumatoid arthritis Giant cell tumor of bone	Amgen	SRE: Ranmark(JP) Osteoporosis: Pralia(JP)
<ul style="list-style-type: none"> • Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (RANKL), a key mediator of the resorptive phase of bone remodeling. • July, 2007 In-licensed from Amgen. • P3 : Breast cancer adjuvant, Rheumatoid arthritis. • [JP] NDA approval: Skeletal Related Event(SRE) in Jan-2012, Osteoporosis in Mar-2013. • [JP] Filed for giant cell tumor of bone in Aug-2013. 						

Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
CS-8958	Ianinamivir	Inhalant	Neuraminidase inhibitor	Influenza, Treatment / Prophylactic	Daiichi Sankyo	Inavir(JP)
<ul style="list-style-type: none"> • Long-acting neuraminidase inhibitor • Licensing activity with Biota in the US and EU, development by Daiichi Sankyo in Japan • CS-8958 is under development as an inhalant that will act directly on the pulmonary and tracheal sites of infection. • [JP] Approved for the flu treatment: Sep-2010. Brand name: Inavir • [JP] Approval for influenza prophylactic in Dec-2013 						
Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DR-3355	levofloxacin	Injection	New quinolone	Anti-infection	Daiichi Sankyo	Cravit (JP) Levaquin (US) Tavanic (EU)
<ul style="list-style-type: none"> • As LCM, additional indications of urinary tract infection, surgical infection and gynecological infection, which are the largest market next to respiratory tract infection are under development. • A P3 comparative study for urinary tract infection and 4 open studies are on-going. 						
Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DS-5565	-	Oral	$\alpha 2\delta$ ligand	Chronic pain	Daiichi Sankyo	TBD
<ul style="list-style-type: none"> • An $\alpha 2\delta$ ligand that binds to $\alpha 2\delta$ subunit of voltage-dependent Ca^{2+} channels • Considered to decrease excess Ca^{2+} influx to nerve terminals and to lower pain-related neurotransmitter release. • Clinical studies are on-going for diabetic peripheral neuropathic pain 						
Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
SUN13837	-	Injection	Modulator of bFGF signaling system	Spinal cord injury	Daiichi Sankyo (Asubio Pharma)	TBD
<ul style="list-style-type: none"> • Although SUN13837 acts upon the signal coupled with the FGF receptor and shows similar cell differentiation actions (nerve cell protection, nerve axon elongation) to bFGF, it does not show any cell multiplication function. • By accelerating self-regeneration capabilities (nerve cell protection, nerve axon elongation) with bFGF like cell differentiation actions, the perceptual and motor-functional dysfunctions caused by cord injuries are to be improved • By making perceptual and motor-functional dysfunctions recovered at an early stage of postinjury, remnant functions in the chronic period are to be improved • Clinical studies are on-going for patients with severe spinal cord injury 						
Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
ASB17061	-	Oral	Chymase inhibitor	Atopic Dermatitis	Daiichi Sankyo (Asubio Pharma)	TBD
<ul style="list-style-type: none"> • Inhibiting chymase, one of endogenous proteases, which is released from mast cells and involves allergic reaction. • Expected to be an oral anti-atopic dermatitis drug with a novel mechanism of action treated with QD dosing. • Clinical study is on-going for adult patients with atopic dermatitis. 						
Development Code Number	Generic Name	Dosage Form	Class	Target Indication	Origin	Brand Name
DS-7113	hydromorphone	Oral/ Injection	opioid mu-receptor regulator	Cancer pain	-	TBD
<ul style="list-style-type: none"> • An opiate, narcotic analgesic that has been available outside of Japan for over 80 years and recommended in WHO guideline as a standard analgesia for cancer pain. • It is designated as unapproved drug by "Study Group on Unapproved and Off-label Drugs of High Medical Need". • Phase 2 clinical study is on-going in patients with cancer pain. 						

MEMO

(This page is intentionally left blank)

1. Summary of Consolidated Income Statement (FY2012)

JPY Bn	Q1			Q2			Q3			Q4			FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	242.6	+4.7%	100%	241.6	+7.7%	100%	261.5	+8.8%	100%	252.2	+4.1%	100%	997.9	59.2	+6.3%
Cost of sales	27%	66.7	+11.2%	32%	77.2	+11.9%	33%	86.4	+20.6%	33%	83.4	+22.6%	31%	313.7	45.0	+16.8%
Gross Profit	73%	176.0	+2.5%	68%	164.4	+5.8%	67%	175.1	+3.8%	67%	168.8	-3.1%	69%	684.2	14.1	+2.1%
SG&A expenses	59%	143.4	+11.8%	58%	139.8	+2.3%	53%	138.6	-0.3%	64%	161.8	-3.6%	58%	583.7	11.8	+2.1%
R&D expenses	17%	42.0	+2.5%	19%	45.2	+5.1%	17%	44.6	-0.3%	20%	51.2	-8.9%	18%	183.0	-2.0	-1.1%
A&P expenses	9%	22.7	+9.6%	9%	21.6	-8.9%	10%	25.3	+2.0%	11%	27.2	+2.7%	10%	96.8	1.1	+1.1%
Personnel expenses	14%	34.7	-0.4%	14%	34.2	-4.1%	13%	34.1	+1.2%	16%	40.7	+17.0%	14%	143.7	4.7	+3.4%
Other SG&A expenses	18%	44.0	+39.0%	16%	38.9	+13.1%	13%	34.6	-3.2%	17%	42.7	-15.2%	16%	160.2	8.0	+5.3%
Operating Income	13%	32.5	-25.2%	10%	24.6	+31.2%	14%	36.5	+22.9%	3%	7.0	+10.2%	10%	100.5	2.3	+2.4%
Non-operating income / expenses		8.3			-15.5			9.4			-3.5			-1.4	20.6	
Non-operating income		10.3			-5.3			8.1			4.5			17.6	7.6	
Non-operating expenses		2.0			10.2			-1.2			8.0			19.0	-13.0	
Ordinary Income	17%	40.8	-9.0%	4%	9.0	-58.0%	18%	45.8	+128.3%	1%	3.5	-	10%	99.1	22.9	+30.1%
Extraordinary income / losses		0.6			-5.2			-5.7			3.3			-7.1	35.2	
Extraordinary income		2.0			0.5			0.7			8.9			12.1	-2.7	
Extraordinary losses		1.5			5.7			6.4			5.7			19.2	-37.9	
Income before income taxes and minority interests	17%	41.4	-5.5%	2%	3.8	-79.1%	15%	40.2	-	3%	6.7	-	9%	92.1	58.2	+171.5%
Income taxes / minority interests		21.0			-0.1			13.0			-8.4			25.5	1.9	
Income taxes		16.8			3.0			10.2			-6.0			23.9	-15.9	
Minority interests		4.2			-3.1			2.8			-2.4			1.6	17.8	
Net Income	8%	20.4	-19.4%	2%	4.0	-66.3%	10%	27.1	-	6%	15.1	-	7%	66.6	56.2	+541.6%
Effective tax rate		41%			78%			25%			-90%			26%		
Overseas sales ratio results		54%			48%			44%			49%			49%		

2. Currency Rate (FY2012)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2012	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	80.21	79.42	80.01	83.11	83.11	+4.04
EUR/JPY (average)	102.91	100.64	102.18	107.15	107.15	-1.81
INR/JPY (average)	1.59	1.54	1.50	1.50	1.50	-0.23

3. Segment Information (FY2012)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		183.5	-4.4%		193.9	+4.3%		223.1	+9.0%		211.9	+17.3%		812.4	49.2	+6.5%
Inter-segment sales		0.3			0.3			0.7			0.5			1.8	1.3	
Net sales	100%	183.8	-4.2%	100%	194.2	+4.4%	100%	223.8	+9.2%	100%	212.4	+17.6%	100%	814.2	50.6	+6.6%
Cost of sales	26%	47.9	+16.4%	29%	56.1	+16.2%	30%	67.3	+28.1%	29%	61.2	+35.5%	29%	232.5	45.3	+24.2%
Gross Profit	74%	135.9	-9.9%	71%	138.1	+0.3%	70%	156.5	+2.6%	71%	151.1	+11.6%	71%	581.7	5.2	+0.9%
SG&A expenses	63%	115.9	+4.2%	61%	117.8	-1.1%	54%	121.8	-0.4%	67%	142.3	+1.5%	61%	497.8	4.9	+1.0%
R&D expenses	22%	40.3	+3.1%	22%	43.2	+5.4%	19%	42.8	+0.2%	23%	49.3	-9.2%	22%	175.5	-1.4	-0.8%
Other expenses	41%	75.6	+4.8%	38%	74.6	-4.5%	35%	79.0	-0.8%	44%	93.0	+8.2%	40%	322.2	6.3	+2.0%
Operating Income	11%	20.1	-49.3%	10%	20.3	+8.9%	16%	34.7	+15.1%	4%	8.9	-	10%	84.0	0.3	+0.4%
Non-operating income		2.1			1.0			2.5			1.7			7.3	-0.8	
Non-operating expenses		1.0			1.6			1.2			1.8			5.6	0.8	
Ordinary Income	11%	21.1	-49.2%	10%	19.8	+4.2%	16%	36.1	+16.1%	4%	8.8	-	11%	85.7	-1.3	-1.4%
Extraordinary income		2.0			0.4			0.6			8.9			11.9	-2.4	
Extraordinary losses		1.3			5.7			6.3			2.5			15.8	0.1	
Income before income taxes and minority interests	12%	21.8	-46.2%	7%	14.5	-8.3%	14%	30.4	+2.8%	7%	15.2	-	10%	81.8	-3.8	-4.4%
Income taxes		8.1			4.4			6.9			-4.7			14.7	-36.6	
Minority interests		-0.1			-0.0			0.2			-0.0					
Net Income	7%	13.7	-40.1%	5%	10.2	-4.6%	10%	23.2	+110.3%	9%	19.9	-	8%	67.0	29.7	+79.4%

Ranbaxy Group		Q1			Q2			Q3			Q4			FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY	
Sales to outside customers		59.1	+48.7%		47.6	+24.0%		38.3	+7.5%		40.3	-34.6%		185.4	9.9	+5.7%	
Inter-segment sales		0.7			0.3			0.3			0.4			1.7	0.6		
Net sales	100%	59.8	+49.5%	100%	47.9	+24.1%	100%	38.6	+7.5%	100%	40.8	-34.3%	100%	187.1	10.5	+6.0%	
Cost of sales	33%	19.5	+3.7%	45%	21.5	+3.7%	52%	20.1	+3.0%	56%	22.9	+0.6%	45%	83.9	2.2	+2.7%	
Gross Profit	67%	40.3	+90.0%	55%	26.5	+47.7%	48%	18.5	+12.9%	44%	17.9	-54.5%	55%	103.2	8.4	+8.8%	
SG&A expenses	44%	26.5	+66.2%	44%	20.9	+28.3%	41%	15.7	+0.5%	45%	18.4	-31.2%	44%	81.4	6.9	+9.3%	
R&D expenses	3%	2.0	-12.3%	4%	2.1	-10.7%	5%	1.9	-17.0%	5%	2.1	-11.6%	4%	8.1	-1.2	-12.9%	
Other expenses	41%	24.5	+79.4%	39%	18.7	+35.1%	36%	13.8	+3.6%	40%	16.3	-33.0%	39%	73.3	8.1	+12.5%	
Operating Income	23%	13.8	+161.9%	12%	5.6	+238.2%	7%	2.9	+238.4%	-1%	-0.5	-103.9%	12%	21.8	1.4	+7.0%	
Non-operating income		8.3			-6.2			5.7			2.8			10.4	7.3		
Non-operating expenses		0.8			8.6			-2.5			6.2			13.2	-13.9		
Ordinary Income	36%	21.2	+269.3%	-19%	-9.2	-317.5%	29%	11.0	-	-10%	-3.9	-	10%	19.1	22.6	-	
Extraordinary income		0.0			0.0			0.0			0.0			0.1	-0.9		
Extraordinary losses		0.1			-0.0			0.0			3.2			3.4	-38.0		
Income before income taxes and minority interests	35%	21.1	+267.8%	-19%	-9.2	-321.2%	29%	11.0	-	-17%	-7.1	-	9%	15.9	59.6	-	
Income taxes		6.1			-2.3			3.6			-1.1			6.3	16.5		
Minority interests		0.0			0.0			0.1			0.1			0.2	0.0		
Net Income	25%	15.0	+118.9%	-14%	-6.9	-297.1%	19%	7.4	-	-15%	-6.1	-	5%	9.4	43.1	-	

Inter-segment Transactions

Net sales		-1.0			-0.6			-1.0			-0.9			-3.5		
Cost of sales		-0.7			-0.4			-0.9			-0.7			-2.7		
Gross Profit		-0.3			-0.2			-0.0			-0.2			-0.7		
SG&A expenses		1.1			1.2			1.1			1.2			4.6		
R&D expenses		-0.3			-0.1			-0.1			-0.1			-0.6		
Other expenses		1.4			1.3			1.3			1.3			5.2		
Operating Income		-1.4			-1.4			-1.1			-1.4			-5.3		
Non-operating income		-0.0			-0.1			-0.1			0.0			-0.2		
Non-operating expenses		0.1			0.0			0.0			0.0			0.2		
Ordinary Income		-1.5			-1.5			-1.2			-1.4			-5.7		
Extraordinary income		-			0.0			0.0			0.1			0.1		
Extraordinary losses		0.0			-0.0			0.0			0.0			0.0		
Income before income taxes and minority interests		-1.5			-1.5			-1.2			-1.4			-5.6		
Income taxes		2.6			0.9			-0.3			-0.3			3.0		
Minority interests		4.2			-3.1			2.6			-2.4			1.3		
Net Income		-8.3			0.7			-3.5			1.3			-9.8		

4. Sales by Business Units (FY2012)

	FY2012 Plan	Q1			Q2			Q3			Q4			FY2012			
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	
JPY Bn																	
Consolidated Net Sales	990.0	242.6	+4.7%	25%	241.6	+7.7%	24%	261.5	+8.8%	26%	252.2	+4.1%	26%	997.9	+6.3%	101%	
Japan Company (domestic sales)	440.0	98.2	-2.2%	22%	106.9	+6.3%	24%	124.7	+9.5%	28%	112.7	+18.8%	26%	442.5	+8.0%	101%	
Olmotec	76.0	18.2	-10.8%	24%	19.3	-5.5%	25%	20.9	-7.6%	28%	19.9	+14.3%	26%	78.3	-3.2%	103%	
Rezaltas	16.0	4.0	+38.6%	25%	4.1	+30.6%	26%	4.6	+16.9%	28%	4.3	+20.5%	27%	16.9	+25.7%	106%	
Calblock	10.0	2.7	-14.0%	27%	2.8	-12.9%	28%	2.8	-13.8%	28%	2.6	-5.5%	26%	10.9	-11.8%	109%	
Loxonin	60.0	14.1	-2.0%	24%	15.6	-0.4%	26%	16.2	-6.1%	27%	13.7	+0.0%	23%	59.6	-2.3%	99%	
Cravit	35.0	8.1	-4.2%	23%	8.4	+0.0%	24%	10.6	-2.0%	30%	8.8	+1.6%	25%	35.9	-1.2%	103%	
Nexium	22.0	1.7	-	8%	2.7	+7.1%	13%	8.3	+1254.8%	38%	8.9	+1113.9%	40%	21.6	+452.0%	98%	
Memary	26.0	5.1	+128.7%	20%	5.6	+247.5%	22%	6.6	+135.7%	25%	6.4	+103.0%	25%	23.8	+142.0%	92%	
Mevalotin	26.0	6.5	-25.7%	25%	6.8	-21.8%	26%	6.6	-25.6%	25%	6.0	-12.4%	23%	25.8	-21.9%	99%	
Artist	22.0	5.6	-8.9%	25%	5.6	-9.3%	26%	5.8	-10.9%	27%	5.3	-5.6%	24%	22.4	-8.8%	102%	
Omnipaque	20.0	4.9	-13.2%	25%	5.3	-15.9%	26%	5.4	-16.3%	27%	4.6	-11.1%	23%	20.2	-14.3%	101%	
Urief	11.0	2.7	+0.5%	24%	2.8	+0.1%	25%	3.0	-1.8%	27%	2.7	+5.7%	25%	11.1	+1.0%	101%	
Inavir	11.0	0.4	+10.3%	4%	0.1	-164.9%	1%	2.1	+22.9%	19%	8.6	-2.0%	78%	11.1	+3.8%	101%	
Ranmark	5.0	0.6	-	12%	1.1	-	22%	1.3	-	27%	1.4	-	27%	4.4	-	88%	
Vaccines	not disclosed	5.2	+13.9%	-	8.1	+52.5%	-	11.8	+72.2%	-	4.7	+3.5%	-	29.8	+40.2%	-	
Daiichi Sankyo Espha products	not disclosed	2.8	+16.2%	-	2.7	+12.7%	-	3.0	+2.4%	-	2.6	+20.7%	-	11.1	+12.2%	-	
Daiichi Sankyo Healthcare (OTC)	48.0	10.2	+5.0%	21%	12.8	+1.1%	27%	14.5	+6.1%	30%	9.5	-2.4%	20%	47.1	+2.7%	98%	
Daiichi Sankyo, Inc. (US)	139.0	35.9	+3.7%	26%	32.6	+10.0%	24%	37.4	+23.9%	27%	36.4	+11.6%	26%	142.3	+12.0%	102%	
Olmesartan	93.0	23.9	-3.8%	26%	21.7	+6.3%	23%	25.7	+24.9%	28%	23.6	+7.0%	25%	94.9	+7.9%	102%	
Benicar/Benicar HCT	73.0	18.9	-6.3%	26%	16.7	-0.6%	23%	20.2	+24.7%	28%	17.4	-3.8%	24%	73.2	+2.8%	100%	
Azor	14.0	3.5	-1.7%	25%	3.5	+40.0%	25%	3.8	+20.9%	27%	4.1	+42.7%	29%	14.8	+23.3%	106%	
Tribenzor	6.0	1.6	+30.8%	26%	1.5	+34.3%	25%	1.6	+37.1%	27%	2.1	+90.9%	35%	6.8	+47.8%	114%	
Welchol	31.0	8.3	+17.5%	27%	7.2	+10.5%	23%	8.3	+26.1%	27%	9.3	+39.4%	30%	33.1	+23.4%	107%	
Effient (alliance revenue)	not disclosed	2.4	+51.8%	-	2.3	+36.4%	-	2.7	+47.5%	-	3.0	+9.5%	-	10.5	+32.7%	-	
Luitpold Pharmaceuticals, Inc. (US)	38.0	11.3	-10.9%	30%	7.7	-17.4%	20%	11.3	-24.7%	30%	8.2	+7.7%	22%	38.6	-13.7%	102%	
Venofer	23.0	6.8	-7.4%	30%	3.8	-30.4%	17%	8.3	-8.5%	36%	4.7	+60.9%	20%	23.6	-4.9%	103%	
Daiichi Sankyo Europe GmbH	65.0	13.9	-17.6%	21%	15.1	-10.8%	23%	16.9	-2.6%	26%	18.5	-3.0%	29%	64.4	-8.3%	99%	
Olmesartan	48.0	9.9	-16.6%	21%	11.3	-6.6%	24%	12.9	+1.8%	27%	13.9	-3.1%	29%	48.0	-5.9%	100%	
Olmotec/Olmotec Plus	34.0	6.4	-26.5%	19%	8.1	-7.6%	24%	8.6	-6.9%	25%	9.4	-4.5%	28%	32.6	-11.1%	96%	
Sevikar	10.0	2.5	+4.5%	25%	2.3	-12.2%	23%	3.1	+17.4%	31%	2.9	-13.7%	29%	10.8	-2.0%	108%	
Sevikar HCT	4.0	1.0	+31.6%	24%	0.9	+25.7%	23%	1.3	+47.9%	32%	1.5	+43.3%	38%	4.7	+38.2%	117%	
Efient (alliance revenue)	not disclosed	0.9	+54.7%	-	0.9	+40.5%	-	0.9	+33.0%	-	1.2	+13.0%	-	3.9	+31.9%	-	
Asia, South and Central America (ASCA)¹	38.0	7.1	+9.8%	19%	8.1	+10.1%	21%	8.2	+18.4%	22%	17.1	+117.8%	45%	40.5	+41.6%	107%	
Daiichi Sankyo China ²	not disclosed	2.7	+0.9%	-	3.0	+16.0%	-	3.1	+50.9%	-	7.6	+214.7%	-	16.4	+68.8%	-	
Daiichi Sankyo Taiwan	not disclosed	0.8	-5.9%	-	0.8	-1.3%	-	0.8	+7.8%	-	0.9	+19.5%	-	3.3	+4.7%	-	
Daiichi Sankyo Korea	not disclosed	1.2	+2.1%	-	1.2	+5.5%	-	1.3	+16.8%	-	1.6	+40.0%	-	5.3	+15.8%	-	
Daiichi Sankyo (Thailand)	not disclosed	0.3	+3.7%	-	0.3	+2.7%	-	0.4	+14.5%	-	0.4	+38.7%	-	1.4	+15.6%	-	
Daiichi Sankyo Brasil Farmacêutica	not disclosed	1.2	+14.2%	-	1.2	-22.5%	-	1.0	-34.4%	-	3.2	+118.5%	-	6.6	+18.6%	-	
Daiichi Sankyo Venezuela	not disclosed	0.8	+87.0%	-	1.4	+49.5%	-	1.5	+37.1%	-	2.9	+75.9%	-	6.7	+60.7%	-	
Daiichi Sankyo Mexico S.A. de C.V	not disclosed	0.1	-	-	0.1	-	-	0.1	-	-	0.4	-	-	0.7	-	-	
Ranbaxy Laboratories Limited	179.0	59.1	+48.7%	33%	47.6	+24.0%	27%	38.3	+7.5%	21%	40.3	-34.6%	23%	185.4	+5.7%	104%	
Others	43.0	6.8	-38.0%	16%	10.7	+13.1%	25%	10.0	+32.8%	23%	9.5	+7.5%	22%	37.1	+0.5%	86%	
Levofloxacin export, royalty, etc	3.0	1.2	-60.1%	41%	1.0	-56.6%	34%	1.4	+19.3%	46%	0.6	-59.6%	21%	4.3	-47.8%	142%	
Plexxikon	not disclosed	0.1	-96.1%	-	1.4	-24.6%	-	1.0	+313.4%	-	0.5	-35.9%	-	3.1	-47.7%	-	

[Reference] Sales in Local Currency

	FY2012 Plan	Q1			Q2			Q3			Q4			FY2012		
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
USD Mn																
Daiichi Sankyo, Inc. (US)	1,711	448	+5.7%	26%	415	+8.7%	24%	461.0	+18.2%	27%	389.0	-5.6%	23%	1,713	+6.5%	100%
Olmesartan	1,144	298	-2.0%	26%	276	+4.9%	24%	317	+19.0%	28%	251	-9.9%	22%	1,142	+2.7%	100%
Benicar/Benicar HCT	898	235	-4.5%	26%	213	-1.8%	24%	249	+18.8%	28%	184	-19.6%	20%	881	-2.2%	98%
Azor	172	44	+0.2%	25%	44	+37.4%	26%	47	+15.5%	27%	44	+22.2%	25%	179	+17.3%	104%
Tribenzor	75	19	+33.3%	26%	19	+33.0%	26%	20	+30.9%	27%	23	+66.5%	31%	82	+40.6%	109%
Welchol	388	103	+19.7%	27%	92	+9.5%	24%	103	+20.3%	27%	101	+19.8%	26%	399	+17.4%	103%
Effient (alliance revenue)	not disclosed	30	+54.7%	-	30	+35.4%	-	34	+41.2%	-	33	-5.7%	-	127	+26.2%	-
USD Mn																
Luitpold Pharmaceuticals, Inc. (US)	468	141	-9.2%	30%	98	-18.5%	21%	140.0	-27.6%	30%	85.0	-11.8%	18%	465	-17.9%	99%
Venofer	288	85	-5.6%	30%	49	-31.0%	17%	103	-11.8%	36%	47	+29.8%	16%	284	-9.6%	99%
EUR Mn																
Daiichi Sankyo Europe GmbH	650	135	-6.0%	21%	153	-0.2%	24%	161.0	-2.6%	25%	152.0	-16.6%	23%	601	-6.7%	93%
Olmesartan	480	96	-4.8%	20%	115	+4.4%	24%	123	+2.0%	26%	114	-16.5%	24%	448	-4.3%	93%
Olmetec/Olmetec Plus	340	62	-16.2%	18%	82	+3.1%	24%	82	-6.8%	24%	78	-17.8%	23%	304	-9.6%	89%
Sevikar	100	24	+19.3%	25%	23	-1.1%	24%	29	+17.7%	29%	23	-26.4%	23%	100	-0.3%	100%
Sevikar HCT	40	9	+50.1%	24%	9	+41.0%	23%	12	+49.4%	30%	13	+27.1%	32%	44	+40.5%	109%
Efient (alliance revenue)	not disclosed	9	+76.5%	-	9	+57.9%	-	9	+33.5%	-	10	-1.0%	-	36	+34.1%	-
INR Bn																
Ranbaxy Laboratories Limited	105	37	+71.1%	35%	32	+53.1%	31%	27.0	+31.2%	26%	27.0	-28.9%	26%	124	+21.9%	117%

5. Sales of Global Products (FY2012)

	FY2012 Plan	Q1			Q2			Q3			Q4			FY2012		
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn																
Olmesartan	251.0	60.0	-5.3%	24%	60.8	+0.6%	24%	68.3	+6.4%	27%	69.7	+13.0%	28%	258.9	+3.7%	103%
Olmetec (JPN)	76.0	18.2	-10.8%	24%	19.3	-5.5%	25%	20.9	-7.6%	28%	19.9	+14.3%	26%	78.3	-3.2%	103%
Rezaltas (JPN)	16.0	4.0	+38.6%	25%	4.1	+30.6%	26%	4.6	+16.9%	28%	4.3	+20.5%	27%	16.9	+25.7%	106%
Benicar/Benicar HCT (US)	73.0	18.9	-6.3%	26%	16.7	-0.6%	23%	20.2	+24.7%	28%	17.4	-3.8%	24%	73.2	+2.8%	100%
Azor (US)	14.0	3.5	-1.7%	25%	3.5	+40.0%	25%	3.8	+20.9%	27%	4.1	+42.7%	29%	14.8	+23.3%	106%
Tribenzor (US)	6.0	1.6	+30.8%	26%	1.5	+34.3%	25%	1.6	+37.1%	27%	2.1	+90.9%	35%	6.8	+47.8%	114%
Olmetec/Olmetec Plus (EU)	34.0	6.4	-26.5%	19%	8.1	-7.6%	24%	8.6	-6.9%	25%	9.4	-4.5%	28%	32.6	-11.1%	96%
Sevikar (EU)	10.0	2.5	+4.5%	25%	2.3	-12.2%	23%	3.1	+17.4%	31%	2.9	-13.7%	29%	10.8	-2.0%	108%
Sevikar HCT (EU)	4.0	1.0	+31.6%	24%	0.9	+25.7%	23%	1.3	+47.9%	32%	1.5	+43.3%	38%	4.7	+38.2%	117%
Other subsidiaries, export, etc	18.0	4.0	+20.6%	22%	4.3	+0.1%	24%	4.3	-3.1%	24%	8.1	+82.8%	45%	20.7	+25.7%	115%
Prasugrel	not disclosed	3.3	+52.6%	-	3.2	+37.5%	-	3.7	+43.5%	-	4.2	+10.4%	-	14.4	+32.5%	-
Effient alliance revenue (US)	not disclosed	2.4	+51.8%	-	2.3	+36.4%	-	2.7	+47.5%	-	3.0	+9.5%	-	10.5	+32.7%	-
Efient alliance revenue (EU)	not disclosed	0.9	+54.7%	-	0.9	+40.5%	-	0.9	+33.0%	-	1.2	+13.0%	-	3.9	+31.9%	-

1. Summary of Consolidated Income Statement (FY2011)

JPY Bn	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	231.7	-9.7%	100%	224.4	-7.5%	100%	240.4	-3.5%	100%	242.3	+10.5%	100%	938.7	-28.7	-3.0%
Cost of sales	26%	59.9	-6.5%	31%	69.0	-7.4%	30%	71.7	-3.9%	28%	68.1	-0.8%	29%	268.6	-13.1	-4.6%
Gross Profit	74%	171.8	-10.7%	69%	155.4	-7.5%	70%	168.7	-3.4%	72%	174.2	+15.6%	71%	670.1	-15.6	-2.3%
SG&A expenses	55%	128.3	-2.3%	61%	136.7	-1.6%	58%	139.0	-3.5%	69%	167.9	+12.5%	61%	571.9	8.3	+1.5%
R&D expenses	18%	41.0	-5.9%	19%	43.0	-5.8%	19%	44.7	-15.6%	23%	56.3	+8.2%	20%	185.1	-9.3	-4.8%
A&P expenses	9%	20.7	-9.4%	11%	23.7	-4.6%	10%	24.8	-4.1%	11%	26.5	+1.4%	10%	95.7	-4.0	-4.0%
Personnel expenses	15%	34.9	+0.8%	16%	35.6	+0.5%	14%	33.7	+1.9%	14%	34.8	+0.0%	15%	139.0	1.1	+0.8%
Other SG&A expenses	14%	31.6	+4.6%	15%	34.4	+4.1%	15%	35.7	+11.3%	21%	50.4	+38.7%	16%	152.1	20.4	+15.5%
Operating Income	19%	43.5	-28.8%	8%	18.7	-35.6%	12%	29.7	-2.8%	3%	6.3	+318.5%	10%	98.2	-23.9	-19.6%
Non-operating income / expenses		1.4			2.8			-9.6			-16.5			-22.0	-31.6	
Non-operating income		4.5			4.8			-1.0			1.7			10.0	-13.2	
Non-operating expenses		3.1			2.0			8.6			18.3			32.0	18.4	
Ordinary Income	19%	44.8	-36.0%	10%	21.5	-4.6%	8%	20.1	-47.1%	-4%	-10.2	-	8%	76.2	-55.5	-42.2%
Extraordinary income / losses		-1.1			-3.2			-41.7			3.7			-42.3	-31.0	
Extraordinary income		1.2			0.7			0.2			12.7			14.8	2.0	
Extraordinary losses		2.3			4.0			41.9			9.0			57.1	32.9	
Income before income taxes and minority interests	19%	43.8	-33.8%	8%	18.3	-34.8%	-9%	-21.6	-	-3%	-6.5	-	4%	33.9	-86.5	-71.8%
Income taxes / minority interests		18.5			6.5			-2.1			0.7			23.5	-26.8	
Income taxes		16.4			6.3			15.2			1.8			39.8	-2.0	
Minority interests		2.1			0.2			-17.4			-1.2			-16.2	-24.7	
Net Income	11%	25.3	-23.5%	5%	11.7	-38.5%	-8%	-19.5	-	-3%	-7.2	-	1%	10.4	-59.7	-85.2%
Effective tax rate		37%			34%			-			-			117%		
Overseas sales ratio results		51%			48%			45%			56%			50%		

2. Currency Rate (FY2011)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2011	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	81.75	79.81	79.00	79.07	79.07	-6.65
EUR/JPY (average)	117.40	113.78	110.62	108.96	108.96	-4.17
INR/JPY (average)	1.83	1.83	1.79	1.73	1.73	-0.20

3. Segment Information (FY2011)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		191.9	-4.8%		185.9	-6.5%		204.7	-4.2%		180.6	-0.4%		763.2	-32.2	-4.2%
Inter-segment sales		0.1			0.1			0.3			-0.0			0.5	0.4	
Net sales	100%	192.0	-4.8%	100%	186.0	-6.4%	100%	205.0	-4.1%	100%	180.6	-0.4%	100%	763.6	-31.8	-4.0%
Cost of sales	21%	41.1	-8.4%	26%	48.3	-11.2%	26%	52.5	-4.4%	25%	45.2	-5.0%	25%	187.1	-14.7	-7.3%
Gross Profit	79%	150.8	-3.8%	74%	137.7	-4.6%	74%	152.5	-3.9%	75%	135.4	+1.2%	76%	576.5	-17.2	-2.9%
SG&A expenses	58%	111.2	-2.0%	64%	119.1	-1.8%	60%	122.3	-4.2%	78%	140.2	+6.6%	65%	492.8	-1.0	-0.2%
R&D expenses	20%	39.1	-3.1%	22%	40.9	-5.9%	21%	42.7	-15.6%	30%	54.2	+9.4%	23%	177.0	-7.0	-3.8%
Other expenses	38%	72.1	-1.4%	42%	78.1	+0.5%	39%	79.6	+3.3%	48%	86.0	+5.0%	41%	315.9	6.0	+1.9%
Operating Income	21%	39.6	-8.5%	10%	18.7	-19.4%	15%	30.2	-2.9%	-3%	-4.8	-	11%	83.7	-16.1	-16.2%
Non-operating income		3.8			1.7			1.6			1.0			8.1	0.9	
Non-operating expenses		1.8			1.4			0.7			0.9			4.8	-2.3	
Ordinary Income	22%	41.6	-4.2%	10%	19.0	-17.8%	15%	31.1	-7.9%	-3%	-4.6	-	11%	87.0	-13.0	-13.0%
Extraordinary income		1.2			0.7			-0.0			12.5			14.3	4.1	
Extraordinary losses		2.3			3.8			1.5			8.1			15.7	-5.2	
Income before income taxes and minority interests	21%	40.4	+1.2%	9%	15.8	-38.9%	14%	29.5	-14.2%	0%	-0.2	-	11%	85.6	-3.7	-4.2%
Income taxes		17.8			5.9			18.9			8.6			51.2	20.7	
Minority interests		-0.2			-0.8			-0.4			-1.6					
Net Income	12%	22.9	+2.5%	6%	10.7	-41.9%	5%	11.0	-57.5%	-4%	-7.2	-	5%	37.4	-21.4	-36.4%

Ranbaxy Group		Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY	
Sales to outside customers		39.8	-27.5%		38.4	-12.0%		35.7	+0.6%		61.6	+62.3%		175.5	3.6	+2.0%	
Inter-segment sales		0.2			0.2			0.2			0.4			1.1	-0.0		
Net sales	100%	40.0	-27.1%	100%	38.6	-11.7%	100%	35.9	+1.1%	100%	62.0	+59.5%	100%	176.6	3.5	+2.0%	
Cost of sales	47%	18.8	-2.2%	54%	20.7	+3.3%	54%	19.5	-0.1%	37%	22.8	+8.2%	46%	81.7	2.0	+2.5%	
Gross Profit	53%	21.2	-40.6%	46%	17.9	-24.5%	46%	16.4	+2.5%	63%	39.3	+120.0%	54%	94.8	1.5	+1.7%	
SG&A expenses	40%	15.9	-2.6%	42%	16.3	-5.0%	43%	15.6	+1.2%	43%	26.7	+59.6%	42%	74.4	8.9	+13.5%	
R&D expenses	6%	2.3	-30.8%	6%	2.4	-21.3%	6%	2.3	-19.1%	4%	2.3	-17.9%	5%	9.3	-2.7	-22.6%	
Other expenses	34%	13.7	+4.5%	36%	13.9	-1.4%	37%	13.3	+5.8%	39%	24.3	+75.4%	37%	65.1	11.6	+21.6%	
Operating Income	13%	5.3	-72.7%	4%	1.7	-74.9%	2%	0.9	+34.5%	20%	12.6	+998.6%	12%	20.4	-7.3	-26.4%	
Non-operating income		1.7			3.1			-2.5			0.8			3.2	-13.0		
Non-operating expenses		1.3			0.5			7.9			17.4			27.0	23.1		
Ordinary Income	14%	5.8	-79.6%	11%	4.2	+353.5%	-26%	-9.5	-	-6%	-3.9	-	-2%	-3.4	-43.4	-	
Extraordinary income		0.0			0.0			0.8			0.2			1.1	-4.1		
Extraordinary losses		0.0			0.1			0.0			41.2			41.4	33.1		
Income before income taxes and minority interests	14%	5.7	-79.2%	11%	4.2	-31.2%	-24%	-8.7	-	-72%	-45.0	-	-25%	-43.8	-80.6	-	
Income taxes		-1.1			0.6			-3.2			-6.5			-10.2	-23.4		
Minority interests		0.0			0.0			0.0			0.0			0.2	-0.1		
Net Income	17%	6.9	-62.7%	9%	3.5	-22.7%	-16%	-5.6	-	-62%	-38.5	-	-19%	-33.7	-57.1	-	

Inter-segment Transactions

	Q1	Q2	Q3	Q4	FY2011
Net sales	-0.3	-0.3	-0.6	-0.4	-1.5
Cost of sales	0.0	-0.1	-0.3	0.1	-0.3
Gross Profit	-0.3	-0.2	-0.2	-0.5	-1.3
SG&A expenses	1.1	1.4	1.1	1.0	4.6
R&D expenses	-0.4	-0.3	-0.3	-0.3	-1.2
Other expenses	1.4	1.7	1.4	1.3	5.8
Operating Income	-1.4	-1.6	-1.3	-1.5	-5.9
Non-operating income	-1.1	-0.1	-0.1	-0.1	-1.3
Non-operating expenses	0.0	0.0	0.1	0.0	0.1
Ordinary Income	-2.5	-1.7	-1.5	-1.7	-7.3
Extraordinary income	0.1	0.0	-0.7	0.0	-0.6
Extraordinary losses			40.3	-40.3	0.0
Income before income taxes and minority interests	-2.4	-1.7	-42.5	38.7	-7.9
Income taxes	-0.3	-0.2	-0.5	-0.2	-1.3
Minority interests	2.3	1.0	-17.0	0.4	-13.4
Net Income	-4.4	-2.4	-24.9	38.5	6.7

4. Sales by Business Units (FY2011)

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn															
Consolidated Net Sales	231.7	-9.7%	24%	224.4	-7.5%	23%	240.4	-3.5%	25%	242.3	+10.5%	25%	938.7	-3.0%	97%
Japan Company (domestic sales)	100.4	-4.6%	23%	100.5	-2.4%	23%	113.9	-2.4%	26%	94.9	+4.3%	22%	409.8	-1.5%	94%
Olmotec	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Calblock	3.2	-13.4%	21%	3.2	-9.4%	21%	3.3	-13.8%	22%	2.7	-7.5%	18%	12.4	-11.3%	83%
Loxonin	14.4	+10.7%	25%	15.7	+13.3%	27%	17.2	+17.6%	30%	13.7	+8.3%	24%	61.0	+12.7%	105%
Cravit	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Nexium	-	-	-	2.6	-	-	0.6	-	-	0.7	-	-	3.9	-	-
Mearny	2.2	-	-	1.6	-	-	2.8	-	-	3.2	-	-	9.8	-	-
Mevalotin	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Artist	6.1	+0.0%	27%	6.2	+6.8%	27%	6.5	+3.6%	29%	5.6	+3.7%	25%	24.5	+3.5%	107%
Omnipaque	5.7	-11.6%	25%	6.3	-5.1%	27%	6.4	-2.0%	28%	5.2	-4.5%	23%	23.5	-5.8%	102%
Urief	2.6	+6.8%	24%	2.8	+13.6%	25%	3.0	+7.6%	27%	2.6	+9.2%	23%	11.0	+9.3%	100%
Inavir	0.4	-	4%	-0.1	-	-	1.7	-38.5%	19%	8.7	+125.1%	97%	10.7	+61.7%	119%
Vaccines	4.6	+166.4%	-	5.3	+14.8%	-	6.9	-19.7%	-	4.5	+56.5%	-	21.2	+19.6%	-
Daiichi Sankyo Espha products	2.4	-	-	2.4	-	-	2.9	-	-	2.1	-	-	9.9	-	-
Daiichi Sankyo Healthcare (OTC)	9.7	+4.9%	20%	12.7	+8.2%	26%	13.7	+4.1%	28%	9.7	-8.5%	20%	45.9	+2.3%	94%
Daiichi Sankyo, Inc. (US)	34.6	+3.2%	27%	29.7	-12.4%	23%	30.1	-13.0%	23%	32.6	+15.0%	25%	127.1	-2.6%	98%
Olmesartan	24.9	-1.5%	28%	20.4	-17.4%	23%	20.6	-16.3%	23%	22.1	+10.7%	25%	87.9	-6.9%	100%
Benicar/Benicar HCT	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Welchol	7.0	+0.5%	22%	6.5	-11.5%	20%	6.6	-16.0%	21%	6.7	+6.7%	21%	26.9	-5.8%	84%
Effient (alliance revenue)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
Luitpold Pharmaceuticals, Inc. (US)	12.7	-13.6%	26%	9.3	-31.7%	19%	15.0	+31.0%	31%	7.6	-45.6%	16%	44.7	-17.0%	91%
Venofer	7.4	-12.5%	30%	5.5	-28.5%	22%	9.1	+55.6%	36%	2.9	-66.8%	12%	24.8	-19.0%	99%
Daiichi Sankyo Europe GmbH	16.9	+14.0%	22%	16.9	+2.0%	22%	17.4	-4.3%	23%	19.1	+13.0%	25%	70.2	+5.7%	91%
Olmesartan	11.9	+23.5%	22%	12.2	+4.2%	22%	12.7	-5.4%	23%	14.3	+24.4%	26%	51.0	+10.5%	93%
Olmotec/Olmotec Plus	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Efient (alliance revenue)	0.6	-	-	0.6	-	-	0.7	-	-	1.0	-	-	2.9	-	-
Asia, South and Central America (ASCA)	6.5	+8.7%	22%	7.3	+3.8%	24%	6.9	+2.0%	23%	7.8	+2.8%	26%	28.6	+4.1%	95%
Daiichi Sankyo Pharmaceutical (Beijing)	0.9	-19.9%	-	0.9	-15.0%	-	0.8	-28.4%	-	0.8	-11.1%	-	3.4	-18.9%	-
Daiichi Sankyo Pharmaceutical (Shanghai)	1.7	+21.9%	-	1.7	-3.8%	-	1.3	-18.7%	-	1.6	-11.3%	-	6.3	-3.9%	-
Daiichi Sankyo Taiwan	0.8	+4.6%	-	0.8	-2.8%	-	0.8	-2.7%	-	0.8	-21.0%	-	3.1	-6.3%	-
Daiichi Sankyo Korea	1.2	+23.0%	-	1.1	+27.0%	-	1.1	+14.6%	-	1.1	-0.7%	-	4.6	+15.2%	-
Daiichi Sankyo (Thailand)	0.3	+10.1%	-	0.3	+2.3%	-	0.3	-1.6%	-	0.3	-7.5%	-	1.2	-0.1%	-
Daiichi Sankyo Brasil Farmacêutica	1.1	+2.6%	-	1.5	+4.4%	-	1.5	+6.7%	-	1.5	+13.1%	-	5.5	+6.9%	-
Daiichi Sankyo Venezuela	0.5	+22.5%	-	1.0	+33.2%	-	1.1	+74.6%	-	1.6	+43.6%	-	4.2	+45.1%	-
Daiichi Sankyo Mexico S.A. de C.V	-	-	-	-	-	-	0.1	-	-	0.1	-	-	0.2	-	-
Ranbaxy Laboratories Limited	39.8	-27.5%	25%	38.4	-12.0%	24%	35.7	+0.6%	22%	61.6	+62.3%	38%	175.5	+2.1%	108%
Others	11.1	-38.7%	29%	9.5	-25.9%	25%	7.5	-40.5%	20%	8.8	-31.2%	23%	36.9	-34.5%	97%
Levofloxacin export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Plexikon	3.0	-	-	1.9	-	-	0.3	-	-	0.8	-	-	5.9	-	-

[Reference] Sales in Local Currency

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
USD Mn															
Daiichi Sankyo, Inc. (US)	424	+16.1%	27%	382	-2.9%	24%	390	-7.5%	25%	412.0	+20.3%	26%	1,608	+5.6%	103%
Olmesartan	304	+10.9%	29%	263	-8.4%	25%	266	-11.2%	25%	278	+15.7%	26%	1,112	+0.9%	105%
Benicar/Benicar HCT	246	+5.7%	31%	217	-10.0%	27%	210	-16.5%	26%	228	+11.5%	28%	901	-3.1%	112%
Azor	43	+4.7%	27%	32	-18.4%	20%	41	-3.5%	25%	36	+11.9%	22%	152	-1.9%	94%
Tribenzor	14	-	16%	14	+96.0%	16%	15	+158.0%	17%	14	+287.9%	16%	58	+244.1%	65%
Welchol	86	+13.2%	22%	84	-1.9%	22%	85	-10.5%	22%	84	+11.6%	22%	340	+2.1%	88%
Effient (alliance revenue)	20	+401.5%	-	22	+151.6%	-	24	+90.2%	-	35	+134.1%	-	100	+150.1%	-
USD Mn															
Luitpold Pharmaceuticals, Inc. (US)	156	-2.8%	26%	121	-24.2%	21%	193	+36.4%	33%	96.0	-42.8%	16%	566	-10.0%	96%
Venofer	90	-1.5%	30%	71	-20.7%	24%	116	+60.8%	39%	36	-65.0%	12%	314	-12.2%	104%
EUR Mn															
Daiichi Sankyo Europe GmbH	144	+13.6%	21%	153	+2.7%	23%	165	+2.5%	25%	182.0	+21.5%	27%	644	+9.8%	96%
Olmesartan	101	+23.1%	21%	110	+5.1%	23%	121	+1.3%	25%	136	+33.5%	29%	468	+14.7%	98%
Olmetec/Olmetec Plus	74	+9.4%	21%	80	-4.4%	23%	88	-2.0%	25%	95	+13.4%	27%	336	+3.7%	97%
Sevikar	21	+43.7%	20%	24	+11.5%	23%	25	+21.1%	24%	32	+75.2%	30%	101	+35.9%	97%
Sevikar HCT	6	-	24%	6	-	25%	8	-10.6%	31%	10	+1366.1%	39%	31	+218.7%	119%
Efient (alliance revenue)	5	-	-	6	-	-	7	-	-	10	-	-	27	-	-
INR Bn															
Ranbaxy Laboratories Limited	22	-21.5%	26%	21	-1.5%	25%	21	+8.0%	25%	38.0	+82.4%	45%	101	+13.9%	119%

5. Sales of Global Products (FY2011)

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn															
Olmesartan	63.3	+5.2%	24%	60.4	-1.6%	22%	64.2	-2.3%	24%	61.7	+13.9%	23%	249.7	+3.4%	93%
Olmetec (JPN)	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas (JPN)	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Benicar/Benicar HCT (US)	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor (US)	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor (US)	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Olmetec/Olmetec Plus (EU)	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar (EU)	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT (EU)	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Other subsidiaries, export, etc	3.3	+16.4%	20%	4.3	+10.4%	25%	4.4	+28.8%	26%	4.5	+18.3%	26%	16.5	+18.3%	97%
Levofloxacin	13.5	-20.2%	26%	12.8	-24.1%	24%	13.9	-23.3%	26%	12.2	-29.1%	23%	52.4	-24.2%	99%
Cravit (JPN)	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Other subsidiaries	2.0	-4.7%	25%	2.1	-4.9%	26%	1.9	-12.9%	23%	2.0	-11.9%	25%	7.9	-8.6%	99%
Pravastatin	10.2	-13.9%	27%	10.0	-15.5%	26%	10.6	-8.6%	28%	8.4	-12.6%	22%	39.2	-12.7%	103%
Mevalotin (JPN)	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Other subsidiaries, export, etc	1.5	-12.9%	25%	1.3	-22.1%	22%	1.7	+10.7%	29%	1.6	-15.1%	26%	6.1	-10.4%	102%
Prasugrel	2.2	+176.5%	-	2.3	+134.2%	-	2.6	+72.6%	-	3.8	+94.3%	-	10.9	+108.2%	-
Effient alliance revenue (US)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
Effient alliance revenue (EU)	0.6	+34.9%	-	0.6	+165.9%	-	0.7	+65.5%	-	1.0	+47.9%	-	2.9	+64.8%	-

1. Summary of Consolidated Income Statement (FY2010)

JPY Bn	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	256.4	+12.9%	100%	242.5	-0.4%	100%	249.2	-2.3%	100%	219.3	-3.2%	100%	967.4	15.3	+1.6%
Cost of sales	25%	64.1	+2.5%	31%	74.4	-0.4%	30%	74.6	-1.1%	31%	68.6	+5.0%	29%	281.7	3.6	+1.3%
Gross Profit	75%	192.4	+16.9%	69%	168.0	-0.4%	70%	174.6	-2.8%	69%	150.7	-6.4%	71%	685.7	11.6	+1.7%
SG&A expenses	51%	131.3	-4.7%	57%	139.0	-3.9%	58%	144.1	+2.6%	68%	149.2	-4.1%	58%	563.5	-15.0	-2.6%
R&D expenses	17%	43.6	-3.4%	19%	45.7	-6.7%	21%	53.0	+11.4%	24%	52.0	-5.6%	20%	194.3	-2.5	-1.3%
Other expenses	34%	87.7	-5.4%	38%	93.3	-2.5%	37%	91.1	-2.0%	44%	97.2	-3.3%	38%	369.2	-12.5	-3.3%
Operating Income	24%	61.1	+128.1%	12%	29.0	+20.6%	12%	30.5	-22.2%	1%	1.5	-72.2%	13%	122.1	26.6	+27.9%
Non-operating income / expenses		9.0			-6.5			7.4			-0.4			9.6	2.0	
Non-operating income		11.8			-1.7			7.5			5.6			23.2	-5.0	
Non-operating expenses		2.8			4.8			0.0			6.0			13.6	-7.0	
Ordinary Income	27%	70.1	+877.7%	9%	22.6	-50.0%	15%	38.0	-1.1%	1%	1.2	-90.7%	14%	131.8	28.6	+27.8%
Extraordinary income / losses		-4.0			5.5			-1.2			-11.6			-11.3	-5.6	
Extraordinary income		0.8			6.8			0.9			4.3			12.8	6.9	
Extraordinary losses		4.8			1.3			2.2			15.9			24.2	12.5	
Income before income taxes and minority interests	26%	66.1	+665.1%	12%	28.0	-37.7%	15%	36.7	-1.6%	-5%	-10.4	-	12%	120.4	23.0	+23.7%
Income taxes / minority interests		33.0			9.0			9.2			-0.9			50.3	-5.2	
Income taxes		26.6			8.2			8.0			-0.9			41.8	-8.2	
Minority interests		6.5			0.8			1.2			0.0			8.5	3.0	
Net Income	13%	33.1	-	8%	19.1	-24.1%	11%	27.5	+33.8%	-4%	-9.5	-	7%	70.1	28.3	+67.5%
Effective tax rate		40%			29%			22%			-			35%		
Overseas sales ratio results		52%			51%			46%			53%			51%		

2. Currency Rate (FY2010)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2010	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	92.02	88.95	86.53	85.72	85.72	-7.14
EUR/JPY (average)	117.00	113.84	113.31	113.13	113.13	-18.03
INR/JPY (average)	1.98	2.01	1.96	1.93	1.93	-0.02

3. Segment Information (FY2010)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	201.6	+2.1%	100%	198.8	-4.0%	100%	213.7	-2.4%	100%	181.3	-0.3%	100%	795.5	-10.0	-1.2%
Cost of sales	22%	44.9	-1.1%	27%	54.4	+0.1%	26%	55.0	-1.1%	26%	47.6	+0.5%	25%	201.8	-0.8	-0.4%
Gross Profit	78%	156.7	+3.1%	73%	144.4	-5.4%	74%	158.8	-2.9%	74%	133.8	-0.6%	75%	593.7	-9.1	-1.5%
SG&A expenses	56%	113.5	-7.0%	61%	121.2	-4.2%	60%	127.7	+2.7%	73%	131.5	-2.5%	62%	493.9	-13.7	-2.7%
R&D expenses	20%	40.3	-6.2%	22%	43.5	-6.9%	24%	50.6	+12.0%	27%	49.6	-4.0%	23%	184.0	-2.5	-1.3%
Other expenses	36%	73.2	-7.4%	39%	77.7	-2.6%	36%	77.1	-2.6%	45%	81.9	-1.5%	39%	309.9	-11.2	-3.5%
Operating Income	22%	43.3	+44.0%	12%	23.2	-11.6%	15%	31.1	-20.6%	1%	2.3	-1422.3%	13%	99.8	4.6	+4.8%
Non-operating income		1.8			1.9			2.6			0.9			7.2	0.2	
Non-operating expenses		1.7			2.0			-0.1			3.4			7.0	0.9	
Ordinary Income	22%	43.4	+34.8%	12%	23.1	-12.6%	16%	33.7	-12.9%	0%	-0.2	-	13%	100.0	3.8	+4.0%
Extraordinary income		0.8			3.8			1.4			4.3			10.2	5.7	
Extraordinary losses		4.2			1.0			0.7			15.0			20.9	9.3	
Income before income taxes and minority interests	20%	40.0	+18.8%	13%	25.9	-1.6%	16%	34.4	-8.6%	-6%	-10.9	-	11%	89.3	0.2	+0.2%
Income taxes		17.7			7.5			8.5			-3.1			30.6	-23.7	
Minority interests																
Net Income	11%	22.3	+122.8%	9%	18.3	+39.4%	12%	26.0	+30.0%	-4%	-7.8	-	7%	58.8	23.9	+68.6%
Ranbaxy Group																
Net sales	100%	54.9	+84.9%	100%	43.8	+20.1%	100%	35.5	-1.4%	100%	38.9	-12.6%	100%	173.1	26.4	+18.0%
Cost of sales	35%	19.2	+12.0%	46%	20.0	-1.8%	55%	19.5	-1.7%	54%	21.0	+16.6%	46%	79.8	4.4	+5.8%
Gross Profit	65%	35.7	+184.1%	54%	23.7	+48.0%	45%	16.0	-1.1%	46%	17.9	-32.5%	54%	93.3	22.1	+31.0%
SG&A expenses	30%	16.4	+13.9%	39%	17.1	+2.9%	43%	15.4	+5.3%	43%	16.7	-13.5%	38%	65.6	0.7	+1.0%
R&D expenses	6%	3.3	+56.2%	7%	3.0	+32.0%	8%	2.8	+19.0%	7%	2.8	-19.0%	7%	12.0	1.7	+16.7%
Other expenses	24%	13.1	+6.7%	32%	14.1	-1.8%	35%	12.5	+2.6%	36%	13.9	-12.3%	31%	53.5	-1.1	-2.0%
Operating Income	35%	19.3	-1171.9%	15%	6.6	-1214.7%	2%	0.6	-60.0%	3%	1.1	-83.9%	16%	27.7	21.4	+338.8%
Non-operating income		10.0			-3.0			4.9			4.2			16.2	-5.0	
Non-operating expenses		1.1			2.7			0.1			0.1			3.9	-10.5	
Ordinary Income	52%	28.3	-220.1%	2%	0.9	-95.4%	16%	5.5	+374.9%	14%	5.3	-65.1%	23%	40.0	27.0	+207.8%
Extraordinary income		0.0			5.2			0.0			-0.1			5.1	3.8	
Extraordinary losses		0.7			0.1			1.5			6.0			8.3	8.2	
Income before income taxes and minority interests	50%	27.6	-217.5%	14%	6.0	-70.2%	11%	4.0	+249.7%	-2%	-0.8	-	21%	36.8	22.6	+158.6%
Income taxes		9.2			1.5			0.1			2.4			13.2	3.4	
Minority interests		0.1			0.1			0.1			0.1			0.3	0.1	
Net Income	33%	18.4	-	10%	4.5	-68.3%	11%	3.8	-	-9%	-3.3	-	14%	23.3	19.1	+456.4%
Inter-segment Transactions																
Net sales		-0.1			-0.1			-0.1			-0.9			-1.2		
Cost of sales		0.0			0.0			0.1			0.0			0.1		
Gross Profit		-0.1			-0.1			-0.2			-0.9			-1.3		
SG&A expenses		1.5			0.7			1.0			1.0			4.1		
R&D expenses		0.0			-0.8			-0.4			-0.4			-1.7		
Other expenses		1.5			1.5			1.4			1.4			5.8		
Operating Income		-1.5			-0.7			-1.2			-1.9			-5.4		
Non-operating income		0.0			-0.7			-0.1			0.5			-0.2		
Non-operating expenses					0.1			0.0			2.5			2.6		
Ordinary Income		-1.5			-1.5			-1.3			-3.9			-8.2		
Extraordinary income		0.0			-2.2			-0.5			0.1			-2.5		
Extraordinary losses					0.2			0.0			-5.2			-5.0		
Income before income taxes and minority interests		-1.5			-3.9			-1.7			1.4			-5.7		
Income taxes		-0.3			-0.8			-0.6			-0.2			-2.0		
Minority interests		6.4			0.7			1.1			-0.1			8.2		
Net Income		-7.6			-3.8			-2.2			1.6			-12.0		

4. Sales by Business Units (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Consolidated Net Sales	256.4	+12.9%	242.5	-0.4%	249.2	-2.3%	219.3	-3.2%	967.4	+1.6%
Japan Company (domestic sales)	105.3	+0.6%	103.0	-1.7%	116.8	-1.4%	91.0	+7.6%	416.0	+0.9%
Olmotec	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Calblock	3.7	+6.5%	3.5	+0.6%	3.8	-0.6%	2.9	+1.3%	14.0	+1.9%
Loxonin	13.0	+15.9%	13.9	+11.0%	14.7	+10.0%	12.6	+27.3%	54.2	+15.3%
Cravit	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Mevalotin	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Artist	6.1	+1.8%	5.8	-1.6%	6.3	-0.9%	5.4	+8.5%	23.7	+1.6%
Omnipaque	6.4	-10.1%	6.6	-12.4%	6.5	-8.5%	5.4	-0.2%	25.0	-8.3%
Urief	2.5	+11.2%	2.5	+9.2%	2.8	+9.2%	2.3	+16.5%	10.1	+11.3%
Inavir	-	-	-	-	2.8	-	3.9	-	6.6	-
Vaccines	1.7	+36.2%	4.6	+139.8%	8.5	-1.2%	2.9	+128.3%	17.8	+35.6%
Daiichi Sankyo Espha products	-	-	-	-	2.6	-	2.0	-	4.6	-
Daiichi Sankyo Healthcare (OTC)	9.3	-2.7%	11.7	-12.9%	13.2	+9.1%	10.6	+23.2%	44.8	+2.6%
Daiichi Sankyo, Inc. (US)	33.6	+1.7%	33.9	+1.2%	34.6	+0.6%	28.4	-11.6%	130.5	-1.9%
Olmesartan	25.2	+0.6%	24.7	-2.5%	24.6	-6.9%	19.9	-19.8%	94.5	-7.1%
Benicar/Benicar HCT	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor	-	-	0.7	-	0.5	-	0.3	-	1.5	-
Welchol	7.0	+1.8%	7.4	+13.4%	7.9	+7.6%	6.3	-8.3%	28.5	+3.6%
Effient (alliance revenue)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
Luitpold Pharmaceuticals, Inc. (US)	14.7	+10.4%	13.7	+1.3%	11.5	-8.5%	14.0	+10.5%	53.9	+3.5%
Venofer	8.4	+5.2%	7.7	-5.0%	5.8	-27.1%	8.7	+8.4%	30.7	-4.6%
Daiichi Sankyo Europe GmbH	14.8	-14.6%	16.6	-10.0%	18.1	-5.0%	16.9	-17.2%	66.4	-11.7%
Olmesartan	9.6	+4.5%	11.7	+4.5%	13.4	+7.9%	11.5	-14.7%	46.2	-0.2%
Olmotec/Olmotec Plus	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT	-	-	-	-	1.0	-	0.1	-	1.1	-
Asia, South and Central America (ASCA)	5.9	+12.7%	7.1	+12.8%	6.8	+3.3%	7.6	-0.4%	27.4	+6.4%
Daiichi Sankyo Pharmaceutical (Beijing)	1.1	+17.8%	1.1	+3.6%	1.1	-6.3%	0.9	-2.2%	4.2	+2.9%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.4	+35.5%	1.7	+32.5%	1.6	+10.5%	1.8	+20.7%	6.6	+23.8%
Daiichi Sankyo Taiwan	0.8	-8.6%	0.8	+1.0%	0.8	+13.5%	1.0	+29.2%	3.4	+7.9%
Daiichi Sankyo Korea	1.0	+31.4%	0.9	+2.9%	1.0	+9.7%	1.1	+29.6%	4.0	+17.9%
Daiichi Sankyo (Thailand)	0.2	+35.8%	0.3	+22.8%	0.3	+53.4%	0.3	+26.9%	1.2	+33.8%
Daiichi Sankyo Brasil Farmacêutica	1.0	+36.5%	1.4	+39.5%	1.4	+6.4%	1.3	-19.9%	5.2	+9.5%
Daiichi Sankyo Venezuela	0.4	-46.7%	0.7	-18.7%	0.6	-25.1%	1.1	-32.7%	2.9	-30.5%
Ranbaxy Laboratories Limited	54.8	+84.7%	43.7	+19.9%	35.4	-1.6%	38.0	-14.5%	171.9	+17.3%
Others	18.0	+25.6%	12.8	-25.1%	12.7	-20.2%	12.8	-20.0%	56.3	-11.1%
Levofloxacin export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Efient alliance revenue (Europe)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

[Reference] Sales in Local Currency (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
Daiichi Sankyo, Inc. (US)	365	+7.6%	394	+10.2%	422	+10.3%	342	-3.3%	1,522	+6.3%
Olmesartan	274	+6.4%	287	+6.2%	300	+2.3%	241	-12.2%	1,102	+0.6%
Benicar/Benicar HCT	233	+2.7%	241	+1.6%	251	-0.5%	205	-15.2%	930	-2.9%
Azor	42	+33.1%	39	+16.9%	42	+4.6%	32	-1.0%	155	+12.7%
Tribenzor	-	-	7	-	6	-	4	-	17	-
Welchol	76	+7.6%	85	+23.1%	95	+17.8%	76	+0.3%	333	+12.2%
Effient (alliance revenue)	4	-	9	-	13	-	15	-	40	-
USD Mn										
Luitpold Pharmaceuticals, Inc. (US)	160	+16.7%	159	+10.6%	142	+1.2%	168	+20.1%	629	+12.1%
Venofer	92	+11.3%	90	+3.8%	72	-18.5%	104	+17.5%	358	+3.4%
EUR Mn										
Daiichi Sankyo Europe GmbH	126	-3.2%	149	+8.3%	161	+12.1%	150	-7.0%	587	+2.3%
Olmesartan	82	+18.4%	105	+25.4%	119	+27.3%	102	-3.9%	408	+15.7%
Olmetec/Olmetec Plus	68	+8.5%	83	+12.0%	90	+16.1%	83	-7.6%	324	+6.5%
Sevikar	14	+109.5%	21	+136.0%	20	+24.9%	18	+12.8%	74	+53.6%
Sevikar HCT	-	-	-	-	9	-	1	-	10	-
INR Bn										
Ranbaxy Laboratories Limited	28	+76.3%	21	+17.1%	19	+4.6%	21	-9.0%	89	+18.5%

5. Sales of Global Products (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Olmesartan	60.2	+7.6%	61.4	+3.4%	65.7	+1.6%	54.2	-7.0%	241.5	+1.4%
Olmetec (JPN)	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas (JPN)	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Benicar/Benicar HCT (US)	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor (US)	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor (US)	-	-	-	-	0.5	-	0.3	-	1.5	-
Olmetec/Olmetec Plus (EU)	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar (EU)	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT (EU)	-	-	-	-	1.0	-	0.1	-	1.1	-
Other subsidiaries, export, etc	2.8	+7.7%	3.9	+25.4%	3.5	-6.2%	3.8	+0.8%	13.9	+6.0%
Levofloxacin	17.0	-14.3%	16.9	-28.0%	18.1	-18.3%	17.2	-21.1%	69.1	-20.7%
Cravit (JPN)	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Other subsidiaries	2.1	+15.8%	2.2	+10.6%	2.1	+2.0%	2.2	+25.6%	8.7	+12.9%
Pravastatin	11.9	-19.1%	11.8	-21.5%	11.6	-21.8%	9.6	-8.3%	44.9	-18.4%
Mevalotin (JPN)	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Other subsidiaries, export, etc	1.7	-25.8%	1.7	-34.1%	1.6	-20.9%	1.8	-6.1%	6.8	-22.8%
Prasugrel (alliance revenue)	0.8	-	1.0	-	1.5	-	2.0	-	5.2	+889.6%
Effient alliance revenue (US)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
Efient alliance revenue (EU)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%